CindyXinShou的个人主页 - 老虎社区

CindyXinShou

CindyXinShou

暂无个人介绍

IP属地：未知

16关注

7粉丝

0主题

0勋章

2021-11-17

Awaiting

Pfizer asks US officials to OK promising COVID-19 pill

2021-11-14

Good, continue to hold.

These are the next three mega-cap tech stocks you’ll be hearing more about

2021-11-13

Good

Meta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?

2021-11-12

It will go up again

Nvidia shares fell nearly 2% in morning trading

2021-11-01

Wow. Good.

抱歉，原内容已删除

2021-10-28

Wow. Good

Microsoft nearly overtakes Apple as most valuable company

2021-10-14

Good!

Singapore Q3 GDP expands 6.5% y/y, largely matching forecasts

2021-10-05

Ok

SoFi Technologies stock dips after offering $1.1B of convertible notes

2021-09-30

Tell me your opinion about this news...

Meme traders see red as heavily-shorted stocks grow scarcer and old names fall

2021-09-24

How long it will take?

If Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop

2021-09-23

Should I?

Should You Buy Toast Stock? A Breakdown of Restaurant SaaS

2021-09-21

Up somemore

U.S. Stock Futures Advance, Airline shares, Carnival stocks rally

2021-09-20

Great, Nvidia!

3 Stocks to Add to Your Portfolio in a Market Pull-Back

2021-09-18

Yeah, seems like.

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-09-07

Wow. Good.

抱歉，原内容已删除

2021-09-04

Wow… meme

抱歉，原内容已删除

2021-08-31

Omg!!!

抱歉，原内容已删除

2021-08-30

Pinduoduo and JD, yeah!

抱歉，原内容已删除

2021-08-28

Rocket again

Crypto stocks surged in morning trading

2021-08-23

Good!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3578292165234013","uuid":"3578292165234013","gmtCreate":1615215467800,"gmtModify":1617889718125,"name":"CindyXinShou","pinyin":"cindyxinshou","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":16,"tweetSize":61,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":878316717,"gmtCreate":1637148527001,"gmtModify":1637148549552,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Awaiting","listText":"Awaiting","text":"Awaiting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878316717","repostId":"1160710301","repostType":4,"repost":{"id":"1160710301","pubTimestamp":1637147244,"share":"https://www.laohu8.com/m/news/1160710301?lang=&edition=full","pubTime":"2021-11-17 19:07","market":"us","language":"en","title":"Pfizer asks US officials to OK promising COVID-19 pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1160710301","media":"Associated Press","summary":"Pfizer asked U.S. regulators Tuesday to authorize its experimental pill for COVID-19, setting the st","content":"<p>Pfizer asked U.S. regulators Tuesday to authorize its experimental pill for COVID-19, setting the stage for a likely launch this winter of a promising treatment that can be taken at home.</p>\n<p>The company's filing comes as new infections are rising once again in the United States, driven mainly by hot spots in states where colder weather is driving more Americans indoors.</p>\n<p>Pfizer’s pill has been shown to significantly cut the rate of hospitalizations and deaths among people with coronavirus infections. The Food and Drug Administration is already reviewing a competing pill from Merck and several smaller drugmakers are also expected to seek authorization for their own antiviral pills in the coming months.</p>\n<p>“We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the U.S. FDA on its review of our application,\" said Pfizer CEO Albert Bourla, in a statement.</p>\n<p>Specifically, Pfizer wants the drug available for adults who have mild-to-moderate COVID-19 infections and are at risk of becoming seriously ill. That's similar to how other drugs are currently used to treat the disease. But all FDA-authorized COVID-19 treatments require an IV or injection given by a health professional at a hospital or clinic.</p>\n<p>The FDA is holding a public meeting on the Merck pill later this month to get the opinion of outside experts before making its decision. The agency isn’t required to convene such meetings and it’s not yet known whether Pfizer’s drug will undergo a similar public review.</p>\n<p>Some experts predict COVID-19 treatments eventually will be combined to better protect against the worst effects of the virus.</p>\n<p>Pfizer reported earlier this monththat its pill cut hospitalizations and deaths by 89% among high-risk adults who had early symptoms of COVID-19. The company studied its pill in people who were unvaccinated and faced the worst risks from the virus due to age or health problems, such as obesity. If authorized, the FDA will have to weigh making the pill available for vaccinated people dealing with breakthrough infections, since they weren't part of the initial tests.</p>\n<p>For best results, patients need to start taking the pills within three days of symptoms, underscoring the need for speedy testing and diagnosis. That could be a challenge if another COVID-19 surge leads to testing delays and shortages seen last winter.</p>\n<p>Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body. That's different than the Merck pill, which causes tiny mutations in the coronavirus until the point that it can't reproduce itself.</p>\n<p>On Tuesday,Pfizer signed a deal a with U.N.-backed groupto allow generic drugmakers to produce low-cost versions of the pill for certain countries. Merck has a similar deal for its pill, which was authorized in Britain earlier this month.</p>\n<p>The U.S. has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they usually have to be given via time-consuming infusions by health professionals, and limited supplies were strained by the last surge of the delta variant.</p>\n<p>The U.S. government has already committed to purchasing Merck's pill. Federal authorities were in negotiations with Pfizer to buy millions of doses of its pill, according to an official familiar with the matter.</p>","source":"lsy1603278176698","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer asks US officials to OK promising COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer asks US officials to OK promising COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-asks-us-officials-ok-190336933.html><strong>Associated Press</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer asked U.S. regulators Tuesday to authorize its experimental pill for COVID-19, setting the stage for a likely launch this winter of a promising treatment that can be taken at home.\nThe company'...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-asks-us-officials-ok-190336933.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/pfizer-asks-us-officials-ok-190336933.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160710301","content_text":"Pfizer asked U.S. regulators Tuesday to authorize its experimental pill for COVID-19, setting the stage for a likely launch this winter of a promising treatment that can be taken at home.\nThe company's filing comes as new infections are rising once again in the United States, driven mainly by hot spots in states where colder weather is driving more Americans indoors.\nPfizer’s pill has been shown to significantly cut the rate of hospitalizations and deaths among people with coronavirus infections. The Food and Drug Administration is already reviewing a competing pill from Merck and several smaller drugmakers are also expected to seek authorization for their own antiviral pills in the coming months.\n“We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the U.S. FDA on its review of our application,\" said Pfizer CEO Albert Bourla, in a statement.\nSpecifically, Pfizer wants the drug available for adults who have mild-to-moderate COVID-19 infections and are at risk of becoming seriously ill. That's similar to how other drugs are currently used to treat the disease. But all FDA-authorized COVID-19 treatments require an IV or injection given by a health professional at a hospital or clinic.\nThe FDA is holding a public meeting on the Merck pill later this month to get the opinion of outside experts before making its decision. The agency isn’t required to convene such meetings and it’s not yet known whether Pfizer’s drug will undergo a similar public review.\nSome experts predict COVID-19 treatments eventually will be combined to better protect against the worst effects of the virus.\nPfizer reported earlier this monththat its pill cut hospitalizations and deaths by 89% among high-risk adults who had early symptoms of COVID-19. The company studied its pill in people who were unvaccinated and faced the worst risks from the virus due to age or health problems, such as obesity. If authorized, the FDA will have to weigh making the pill available for vaccinated people dealing with breakthrough infections, since they weren't part of the initial tests.\nFor best results, patients need to start taking the pills within three days of symptoms, underscoring the need for speedy testing and diagnosis. That could be a challenge if another COVID-19 surge leads to testing delays and shortages seen last winter.\nPfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body. That's different than the Merck pill, which causes tiny mutations in the coronavirus until the point that it can't reproduce itself.\nOn Tuesday,Pfizer signed a deal a with U.N.-backed groupto allow generic drugmakers to produce low-cost versions of the pill for certain countries. Merck has a similar deal for its pill, which was authorized in Britain earlier this month.\nThe U.S. has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they usually have to be given via time-consuming infusions by health professionals, and limited supplies were strained by the last surge of the delta variant.\nThe U.S. government has already committed to purchasing Merck's pill. Federal authorities were in negotiations with Pfizer to buy millions of doses of its pill, according to an official familiar with the matter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873175199,"gmtCreate":1636900751953,"gmtModify":1636900756497,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Good, continue to hold.","listText":"Good, continue to hold.","text":"Good, continue to hold.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873175199","repostId":"1103944030","repostType":4,"repost":{"id":"1103944030","pubTimestamp":1636857439,"share":"https://www.laohu8.com/m/news/1103944030?lang=&edition=full","pubTime":"2021-11-14 10:37","market":"us","language":"en","title":"These are the next three mega-cap tech stocks you’ll be hearing more about","url":"https://stock-news.laohu8.com/highlight/detail?id=1103944030","media":"MarketWatch","summary":"AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is","content":"<p>AMD is among companies poised to eclipse $200 billion in market value</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8977785546ccb691b11117bea0aa1480\" tg-width=\"1320\" tg-height=\"742\" referrerpolicy=\"no-referrer\"><span>AMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images</span></p>\n<p>As technology stocks have led the market for the better part of a dozen years, there are now 15 companies in the sector that have risen to mega-cap status — those valued at $200 billion or more.</p>\n<p>Five are valued at more than $1 trillion, including electric-vehicle maker Tesla,which I consider a tech company.</p>\n<p>Bets have been placed on which companies will rise to a trillion next, with Meta Platforms&nbsp;— aka Facebook — at the top of most lists and&nbsp;Nvidia,sitting on top of mine as a call I made 14 months ago.</p>\n<p>Perhaps harder than rising from north of half a trillion to a trillion is rising from less than&nbsp;$200 billion&nbsp;to break the threshold into mega-cap status.</p>\n<p>However, a few companies look destined for this outcome precisely, and I believe three have an incredibly compelling case to get there within the next 12 to 18 months — if not sooner.</p>\n<p><b>1. ServiceNow:</b>&nbsp;ServiceNow&nbsp;has been on an incredible run for more than a decade. From 2010 to 2020, revenues grew at a 59.2% average annual rate, while its stock rose at 44% a year. The company finished the 2020 calendar year at about $4.5 billion in revenue, and its trailing 12 months have surged close to $5.5 billion.</p>\n<p>The company now has more than 1,266 customers with a million or more dollars in recurring revenue, and is seeing this number grow at a substantial rate, including 25% in its most recent quarter.</p>\n<p>Beyond the numbers, the company’s technology, which enables companies to automate and implement digital workflows, continues to prove robust and best of breed. The most recent release of its Rome platform, three additional acquisitions to expand its portfolio and a deepened partnership with Microsoft&nbsp;are just a few recent highlights that provide the company a pathway to growth that should accelerate based on trends including app modernization, hybrid work, workflow automation, and even enterprise ESG initiatives.</p>\n<p>It’s hard to see ServiceNow not providing the robust growth that will take its market cap above $200 billion.&nbsp;The company’s market value is about $138 billion as of Monday.</p>\n<p><b>2. Qualcomm:</b>Qualcomm’s&nbsp;strong earnings report released last week — earnings per share jumped 76% year over year and revenue rose 43% — helped drive the stock to over $160 from the low $120s in mid-October.</p>\n<p>Consequently, that took the company’s market cap from about $145 billion to over $180 billion in just a matter of days. It serves as a timely reminder of how quickly a tech company in the right markets can produce momentum.</p>\n<p>Qualcomm, while best known as a chip provider for mobile handsets, is rapidly becoming a much bigger force in many categories, including the internet of things (IoT), automotive and wireless RFFE. With IoT and wireless RFFE surpassing a billion dollars a quarter in revenue, and automotive reaching nearly a billion in annual revenue with a $10 billion design pipeline, the company is becoming increasingly diversified. Thirty-eight percent of revenue in its QCT semiconductor business is now unrelated to handsets.</p>\n<p>Perhaps these adjacent business successes alone could catapult the company’s market value to over $200 billion, but what Qualcomm also has going for it is an undisputable global market leadership in 5G, which will continue to accelerate its handset business, as well as all of its adjacencies and massive licensing business.</p>\n<p><b>3. AMD:</b>&nbsp;I’ve been critical at times of Advanced Micro Devices,and sometimes you have to lean into calls you get wrong. While Intel&nbsp;under new CEO Pat Gelsinger shows more ambition and clear direction, AMD under Lisa Su has been on an absolute tear.</p>\n<p>In August, Mercury Research reported that AMD’s 22.5% x86 market share was its best in 14 years. With 4.2% year-over-year market share growth in its second quarter and another 54% overall revenue growth in the third quarter, the company’s market share gains look likely to continue.</p>\n<p>While I do think Intel is quickly patching its gaps and going to be a much more robust competitor, I believe the overall demand for CPUs (central processing units), GPUs (graphics processing units) and FPGAs (field-programmable gate arrays) will drive a larger total addressable market, and AMD’s going to grow revenues even if market share gains level off.</p>\n<p>Speaking of FPGA’s, the impending Xilinx deal, which I believe will gain regulatory approval, hasn’t been accounted for by many investors.</p>\n<p>AMD’s market value rose to over $180 billion Monday after the stock surged more than 10%. The company on Monday announced a range of news, including the fact that Meta will use its Epyc processors in its data center computers.</p>\n<p>After those three, I would add Micron Technology&nbsp;as an honorable mention. The company sits at closer to $85 billion in market cap. Still, as our thirst for compute continues to grow, the need for memory technology will scale dramatically, making Micron a significant beneficiary along with the likes of Samsung, which already sits well inside mega-cap territory.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the next three mega-cap tech stocks you’ll be hearing more about</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the next three mega-cap tech stocks you’ll be hearing more about\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-14 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images\nAs technology stocks have led the market for the better part of ...</p>\n\n<a href=\"https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NOW":"ServiceNow","NVDA":"英伟达","AMD":"美国超微公司","QCOM":"高通"},"source_url":"https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103944030","content_text":"AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images\nAs technology stocks have led the market for the better part of a dozen years, there are now 15 companies in the sector that have risen to mega-cap status — those valued at $200 billion or more.\nFive are valued at more than $1 trillion, including electric-vehicle maker Tesla,which I consider a tech company.\nBets have been placed on which companies will rise to a trillion next, with Meta Platforms — aka Facebook — at the top of most lists and Nvidia,sitting on top of mine as a call I made 14 months ago.\nPerhaps harder than rising from north of half a trillion to a trillion is rising from less than $200 billion to break the threshold into mega-cap status.\nHowever, a few companies look destined for this outcome precisely, and I believe three have an incredibly compelling case to get there within the next 12 to 18 months — if not sooner.\n1. ServiceNow: ServiceNow has been on an incredible run for more than a decade. From 2010 to 2020, revenues grew at a 59.2% average annual rate, while its stock rose at 44% a year. The company finished the 2020 calendar year at about $4.5 billion in revenue, and its trailing 12 months have surged close to $5.5 billion.\nThe company now has more than 1,266 customers with a million or more dollars in recurring revenue, and is seeing this number grow at a substantial rate, including 25% in its most recent quarter.\nBeyond the numbers, the company’s technology, which enables companies to automate and implement digital workflows, continues to prove robust and best of breed. The most recent release of its Rome platform, three additional acquisitions to expand its portfolio and a deepened partnership with Microsoft are just a few recent highlights that provide the company a pathway to growth that should accelerate based on trends including app modernization, hybrid work, workflow automation, and even enterprise ESG initiatives.\nIt’s hard to see ServiceNow not providing the robust growth that will take its market cap above $200 billion. The company’s market value is about $138 billion as of Monday.\n2. Qualcomm:Qualcomm’s strong earnings report released last week — earnings per share jumped 76% year over year and revenue rose 43% — helped drive the stock to over $160 from the low $120s in mid-October.\nConsequently, that took the company’s market cap from about $145 billion to over $180 billion in just a matter of days. It serves as a timely reminder of how quickly a tech company in the right markets can produce momentum.\nQualcomm, while best known as a chip provider for mobile handsets, is rapidly becoming a much bigger force in many categories, including the internet of things (IoT), automotive and wireless RFFE. With IoT and wireless RFFE surpassing a billion dollars a quarter in revenue, and automotive reaching nearly a billion in annual revenue with a $10 billion design pipeline, the company is becoming increasingly diversified. Thirty-eight percent of revenue in its QCT semiconductor business is now unrelated to handsets.\nPerhaps these adjacent business successes alone could catapult the company’s market value to over $200 billion, but what Qualcomm also has going for it is an undisputable global market leadership in 5G, which will continue to accelerate its handset business, as well as all of its adjacencies and massive licensing business.\n3. AMD: I’ve been critical at times of Advanced Micro Devices,and sometimes you have to lean into calls you get wrong. While Intel under new CEO Pat Gelsinger shows more ambition and clear direction, AMD under Lisa Su has been on an absolute tear.\nIn August, Mercury Research reported that AMD’s 22.5% x86 market share was its best in 14 years. With 4.2% year-over-year market share growth in its second quarter and another 54% overall revenue growth in the third quarter, the company’s market share gains look likely to continue.\nWhile I do think Intel is quickly patching its gaps and going to be a much more robust competitor, I believe the overall demand for CPUs (central processing units), GPUs (graphics processing units) and FPGAs (field-programmable gate arrays) will drive a larger total addressable market, and AMD’s going to grow revenues even if market share gains level off.\nSpeaking of FPGA’s, the impending Xilinx deal, which I believe will gain regulatory approval, hasn’t been accounted for by many investors.\nAMD’s market value rose to over $180 billion Monday after the stock surged more than 10%. The company on Monday announced a range of news, including the fact that Meta will use its Epyc processors in its data center computers.\nAfter those three, I would add Micron Technology as an honorable mention. The company sits at closer to $85 billion in market cap. Still, as our thirst for compute continues to grow, the need for memory technology will scale dramatically, making Micron a significant beneficiary along with the likes of Samsung, which already sits well inside mega-cap territory.","news_type":1},"isVote":1,"tweetType":1,"viewCount":849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879799564,"gmtCreate":1636770294362,"gmtModify":1636770294468,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879799564","repostId":"1116750872","repostType":4,"repost":{"id":"1116750872","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1636761765,"share":"https://www.laohu8.com/m/news/1116750872?lang=&edition=full","pubTime":"2021-11-13 08:02","market":"us","language":"en","title":"Meta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?","url":"https://stock-news.laohu8.com/highlight/detail?id=1116750872","media":"Benzinga","summary":"Meta Platforms Inc is having a strong close thus far to end the week, up almost 3.5% and only $7 off","content":"<p><b>Meta Platforms Inc</b>&nbsp;is having a strong close thus far to end the week, up almost 3.5% and only $7 off the weekly highs.</p>\n<p><b>What Happened:</b>&nbsp;While the volume of shares traded is solid at 17 million vs. the 10 day average of 21 million, options traders are quite active on the day, trading more than&nbsp;672,970 options with 476,002&nbsp;being calls and 196,968&nbsp;being puts. This comes out to about 7 out of every 10 options being calls (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/c08237f8d7c163047e56072f027073d5\" tg-width=\"1001\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>What It Matters:</b>Prior to this Friday, there were 1,519,000 calls and 1,207,750 puts for a total of 2,726,000&nbsp;options. Hence this Friday's options activity and flows of 672,970 comprise 25% of the total option flows out there.</p>\n<p>Any time a stock trades 25% of its total options in one day, it means options traders are particularly active in the stock.</p>\n<p>Of note, only 11% of the options were set to expire this Friday (~300,000 options) so today's 672,970&nbsp;options suggest a lot more forward-looking flows.</p>\n<p><b>What's Next:</b>Looking at the option flows expiring next week on Nov. 19, you can see on the call side the majority of volume and open interest is between the $330 and $360 strikes. And on the put side, there is a consistent but small volume between the $340 and $300 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/e74f74fdf39ce74de7e0d6a88eb349c8\" tg-width=\"1743\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>\n<p>This suggests bullish traders are targeting&nbsp;between $330 and $360, but don't have&nbsp;much appetite above that. Meanwhile, bearish options traders don't see much downside below $300.</p>\n<p>It should be noted the steady volume of puts from $340 to $300 appears to be a mix of bullish traders selling cash-secured puts down to the $322.5 strike, but likely long stock traders seeking protection below that as the premium is very low.</p>\n<p>Hence bullish traders will want to see the $360 strike cleared by next week to lift their expectations higher while bears will want to see a weekly close below $300 to open up the downside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-13 08:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Meta Platforms Inc</b>&nbsp;is having a strong close thus far to end the week, up almost 3.5% and only $7 off the weekly highs.</p>\n<p><b>What Happened:</b>&nbsp;While the volume of shares traded is solid at 17 million vs. the 10 day average of 21 million, options traders are quite active on the day, trading more than&nbsp;672,970 options with 476,002&nbsp;being calls and 196,968&nbsp;being puts. This comes out to about 7 out of every 10 options being calls (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/c08237f8d7c163047e56072f027073d5\" tg-width=\"1001\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>What It Matters:</b>Prior to this Friday, there were 1,519,000 calls and 1,207,750 puts for a total of 2,726,000&nbsp;options. Hence this Friday's options activity and flows of 672,970 comprise 25% of the total option flows out there.</p>\n<p>Any time a stock trades 25% of its total options in one day, it means options traders are particularly active in the stock.</p>\n<p>Of note, only 11% of the options were set to expire this Friday (~300,000 options) so today's 672,970&nbsp;options suggest a lot more forward-looking flows.</p>\n<p><b>What's Next:</b>Looking at the option flows expiring next week on Nov. 19, you can see on the call side the majority of volume and open interest is between the $330 and $360 strikes. And on the put side, there is a consistent but small volume between the $340 and $300 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/e74f74fdf39ce74de7e0d6a88eb349c8\" tg-width=\"1743\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>\n<p>This suggests bullish traders are targeting&nbsp;between $330 and $360, but don't have&nbsp;much appetite above that. Meanwhile, bearish options traders don't see much downside below $300.</p>\n<p>It should be noted the steady volume of puts from $340 to $300 appears to be a mix of bullish traders selling cash-secured puts down to the $322.5 strike, but likely long stock traders seeking protection below that as the premium is very low.</p>\n<p>Hence bullish traders will want to see the $360 strike cleared by next week to lift their expectations higher while bears will want to see a weekly close below $300 to open up the downside.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116750872","content_text":"Meta Platforms Inc is having a strong close thus far to end the week, up almost 3.5% and only $7 off the weekly highs.\nWhat Happened: While the volume of shares traded is solid at 17 million vs. the 10 day average of 21 million, options traders are quite active on the day, trading more than 672,970 options with 476,002 being calls and 196,968 being puts. This comes out to about 7 out of every 10 options being calls (image below).\n\nWhat It Matters:Prior to this Friday, there were 1,519,000 calls and 1,207,750 puts for a total of 2,726,000 options. Hence this Friday's options activity and flows of 672,970 comprise 25% of the total option flows out there.\nAny time a stock trades 25% of its total options in one day, it means options traders are particularly active in the stock.\nOf note, only 11% of the options were set to expire this Friday (~300,000 options) so today's 672,970 options suggest a lot more forward-looking flows.\nWhat's Next:Looking at the option flows expiring next week on Nov. 19, you can see on the call side the majority of volume and open interest is between the $330 and $360 strikes. And on the put side, there is a consistent but small volume between the $340 and $300 strikes (image below).\n\nThis suggests bullish traders are targeting between $330 and $360, but don't have much appetite above that. Meanwhile, bearish options traders don't see much downside below $300.\nIt should be noted the steady volume of puts from $340 to $300 appears to be a mix of bullish traders selling cash-secured puts down to the $322.5 strike, but likely long stock traders seeking protection below that as the premium is very low.\nHence bullish traders will want to see the $360 strike cleared by next week to lift their expectations higher while bears will want to see a weekly close below $300 to open up the downside.","news_type":1},"isVote":1,"tweetType":1,"viewCount":847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879254707,"gmtCreate":1636729989347,"gmtModify":1636729989449,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"It will go up again&nbsp;","listText":"It will go up again&nbsp;","text":"It will go up again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879254707","repostId":"1139324750","repostType":4,"repost":{"id":"1139324750","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636729318,"share":"https://www.laohu8.com/m/news/1139324750?lang=&edition=full","pubTime":"2021-11-12 23:01","market":"us","language":"en","title":"Nvidia shares fell nearly 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1139324750","media":"Tiger Newspress","summary":"Nvidia shares fell nearly 2% in morning trading.Wedbush analyst Matt Bryson downgraded NVIDIA Corp t","content":"<p>Nvidia&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/11eee16e740f662501f2bc3de305f18c\" tg-width=\"871\" tg-height=\"618\" width=\"100%\" height=\"auto\"><b>Wedbush</b>&nbsp;analyst Matt Bryson downgraded&nbsp;<b>NVIDIA Corp</b>&nbsp;to Neutral from&nbsp;Outperform with a price target of $300, up from $220.</p>\n<p>The analyst cites valuation for the downgrade, with the shares trading at 55 times his 2024 numbers.</p>\n<p>He would have to lift the multiple to 67x to justify Outperform, suggesting Nvidia valued at ~7X its stated 2024 TAM and ~25X sales. Conversely, he would have to double his sales growth assumptions (from ~20% to ~40%) over the next couple of years to continue to use a 40X multiple to value Nvidia.</p>\n<p>However, Bryson believes the combination of \"unprecedented demand\" for both data center and client offerings will allow Nvidia to exceed expectations again next week when its reports.</p>\n<p>Nvidia's continued work in building out its AI software will further solidify its AI leadership.</p>\n<p>Client GPUs have again become difficult to source, helped by a combination of solid gaming demand and crypto mining requirements.</p>\n<p>New opportunities, particularly the Metaverse and its graphics-intensive requirements, have started to realize the increased investment.</p>\n<p>He sees no \"negative catalyst\" for the stock and improving fundamentals for Nvidia but downgrades the shares on valuation.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia shares fell nearly 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia shares fell nearly 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-12 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nvidia&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/11eee16e740f662501f2bc3de305f18c\" tg-width=\"871\" tg-height=\"618\" width=\"100%\" height=\"auto\"><b>Wedbush</b>&nbsp;analyst Matt Bryson downgraded&nbsp;<b>NVIDIA Corp</b>&nbsp;to Neutral from&nbsp;Outperform with a price target of $300, up from $220.</p>\n<p>The analyst cites valuation for the downgrade, with the shares trading at 55 times his 2024 numbers.</p>\n<p>He would have to lift the multiple to 67x to justify Outperform, suggesting Nvidia valued at ~7X its stated 2024 TAM and ~25X sales. Conversely, he would have to double his sales growth assumptions (from ~20% to ~40%) over the next couple of years to continue to use a 40X multiple to value Nvidia.</p>\n<p>However, Bryson believes the combination of \"unprecedented demand\" for both data center and client offerings will allow Nvidia to exceed expectations again next week when its reports.</p>\n<p>Nvidia's continued work in building out its AI software will further solidify its AI leadership.</p>\n<p>Client GPUs have again become difficult to source, helped by a combination of solid gaming demand and crypto mining requirements.</p>\n<p>New opportunities, particularly the Metaverse and its graphics-intensive requirements, have started to realize the increased investment.</p>\n<p>He sees no \"negative catalyst\" for the stock and improving fundamentals for Nvidia but downgrades the shares on valuation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139324750","content_text":"Nvidia shares fell nearly 2% in morning trading.Wedbush analyst Matt Bryson downgraded NVIDIA Corp to Neutral from Outperform with a price target of $300, up from $220.\nThe analyst cites valuation for the downgrade, with the shares trading at 55 times his 2024 numbers.\nHe would have to lift the multiple to 67x to justify Outperform, suggesting Nvidia valued at ~7X its stated 2024 TAM and ~25X sales. Conversely, he would have to double his sales growth assumptions (from ~20% to ~40%) over the next couple of years to continue to use a 40X multiple to value Nvidia.\nHowever, Bryson believes the combination of \"unprecedented demand\" for both data center and client offerings will allow Nvidia to exceed expectations again next week when its reports.\nNvidia's continued work in building out its AI software will further solidify its AI leadership.\nClient GPUs have again become difficult to source, helped by a combination of solid gaming demand and crypto mining requirements.\nNew opportunities, particularly the Metaverse and its graphics-intensive requirements, have started to realize the increased investment.\nHe sees no \"negative catalyst\" for the stock and improving fundamentals for Nvidia but downgrades the shares on valuation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849401899,"gmtCreate":1635771092938,"gmtModify":1635771093011,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Wow. Good.","listText":"Wow. Good.","text":"Wow. Good.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849401899","repostId":"1178084049","repostType":4,"isVote":1,"tweetType":1,"viewCount":583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855720118,"gmtCreate":1635403802747,"gmtModify":1635403802849,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Wow. Good","listText":"Wow. Good","text":"Wow. Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855720118","repostId":"2178237269","repostType":4,"repost":{"id":"2178237269","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635376679,"share":"https://www.laohu8.com/m/news/2178237269?lang=&edition=full","pubTime":"2021-10-28 07:17","market":"us","language":"en","title":"Microsoft nearly overtakes Apple as most valuable company","url":"https://stock-news.laohu8.com/highlight/detail?id=2178237269","media":"Reuters","summary":"(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuabl","content":"<p>(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuable company on Wednesday, a day before the iPhone maker reports its quarterly results.</p>\n<p>Fueled by strong quarterly growth in its Azure cloud-computing business, Microsoft's shares jumped 4.2% to end at a record $323.17, elevating the software maker's market capitalization to $2.426 trillion, just short of Apple's $2.461 trillion valuation, according to Refinitiv data.</p>\n<p>Apple's shares dipped 0.3% ahead of its report due after the bell on Thursday, with investors focused on how the global supply-chain crisis is challenging the company's ability to meet demand for its iPhones.</p>\n<p>Microsoft's stock has rallied 45% this year, with pandemic-induced demand for its cloud-based services driving sales. Shares of Apple have climbed 12% in 2021.</p>\n<p>Apple's stock market value overtook Microsoft's in 2010 as the iPhone made it the world's premier consumer technology company. The two companies have taken turns as Wall Street's most valuable company in recent years, with Apple holding the title since mid-2020.</p>\n<p>In its report late on Tuesday, Microsoft forecast a strong end to the calendar year thanks to its booming cloud business, but it warned that supply-chain woes will continue to dog key units, such as those producing its Surface laptops and Xbox gaming consoles.</p>\n<p>Analysts on average expect Apple to report September-quarter revenue up 31% to $84.8 billion and adjusted earnings per share of $1.24, according to Refinitiv.</p>\n<p>Read:<a href=\"https://laohu8.com/NW/1178636160\" target=\"_blank\">Apple Reports Earnings Thursday. Here’s What to Expect.</a></p>\n<p>Read:<a href=\"https://laohu8.com/NW/1188688981\" target=\"_blank\">Amazon Earnings Are Coming Thursday. Here’s What to Expect.</a></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft nearly overtakes Apple as most valuable company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft nearly overtakes Apple as most valuable company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-28 07:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuable company on Wednesday, a day before the iPhone maker reports its quarterly results.</p>\n<p>Fueled by strong quarterly growth in its Azure cloud-computing business, Microsoft's shares jumped 4.2% to end at a record $323.17, elevating the software maker's market capitalization to $2.426 trillion, just short of Apple's $2.461 trillion valuation, according to Refinitiv data.</p>\n<p>Apple's shares dipped 0.3% ahead of its report due after the bell on Thursday, with investors focused on how the global supply-chain crisis is challenging the company's ability to meet demand for its iPhones.</p>\n<p>Microsoft's stock has rallied 45% this year, with pandemic-induced demand for its cloud-based services driving sales. Shares of Apple have climbed 12% in 2021.</p>\n<p>Apple's stock market value overtook Microsoft's in 2010 as the iPhone made it the world's premier consumer technology company. The two companies have taken turns as Wall Street's most valuable company in recent years, with Apple holding the title since mid-2020.</p>\n<p>In its report late on Tuesday, Microsoft forecast a strong end to the calendar year thanks to its booming cloud business, but it warned that supply-chain woes will continue to dog key units, such as those producing its Surface laptops and Xbox gaming consoles.</p>\n<p>Analysts on average expect Apple to report September-quarter revenue up 31% to $84.8 billion and adjusted earnings per share of $1.24, according to Refinitiv.</p>\n<p>Read:<a href=\"https://laohu8.com/NW/1178636160\" target=\"_blank\">Apple Reports Earnings Thursday. Here’s What to Expect.</a></p>\n<p>Read:<a href=\"https://laohu8.com/NW/1188688981\" target=\"_blank\">Amazon Earnings Are Coming Thursday. Here’s What to Expect.</a></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178237269","content_text":"(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuable company on Wednesday, a day before the iPhone maker reports its quarterly results.\nFueled by strong quarterly growth in its Azure cloud-computing business, Microsoft's shares jumped 4.2% to end at a record $323.17, elevating the software maker's market capitalization to $2.426 trillion, just short of Apple's $2.461 trillion valuation, according to Refinitiv data.\nApple's shares dipped 0.3% ahead of its report due after the bell on Thursday, with investors focused on how the global supply-chain crisis is challenging the company's ability to meet demand for its iPhones.\nMicrosoft's stock has rallied 45% this year, with pandemic-induced demand for its cloud-based services driving sales. Shares of Apple have climbed 12% in 2021.\nApple's stock market value overtook Microsoft's in 2010 as the iPhone made it the world's premier consumer technology company. The two companies have taken turns as Wall Street's most valuable company in recent years, with Apple holding the title since mid-2020.\nIn its report late on Tuesday, Microsoft forecast a strong end to the calendar year thanks to its booming cloud business, but it warned that supply-chain woes will continue to dog key units, such as those producing its Surface laptops and Xbox gaming consoles.\nAnalysts on average expect Apple to report September-quarter revenue up 31% to $84.8 billion and adjusted earnings per share of $1.24, according to Refinitiv.\nRead:Apple Reports Earnings Thursday. Here’s What to Expect.\nRead:Amazon Earnings Are Coming Thursday. Here’s What to Expect.","news_type":1},"isVote":1,"tweetType":1,"viewCount":770,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825049890,"gmtCreate":1634182106046,"gmtModify":1634182106116,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825049890","repostId":"2175615162","repostType":4,"repost":{"id":"2175615162","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1634170260,"share":"https://www.laohu8.com/m/news/2175615162?lang=&edition=full","pubTime":"2021-10-14 08:11","market":"sg","language":"en","title":"Singapore Q3 GDP expands 6.5% y/y, largely matching forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2175615162","media":"Reuters","summary":"SINGAPORE, Oct 14 (Reuters) - Singapore's economy grew 6.5% in the third quarter, preliminary offici","content":"<p>SINGAPORE, Oct 14 (Reuters) - Singapore's economy grew 6.5% in the third quarter, preliminary official data showed on Thursday, broadly in line with economists' forecast.</p>\n<p>Economists polled by Reuters had expected an expansion of 6.6% year-on-year for the third quarter.</p>\n<p>Gross domestic product had jumped 15.2% year-on-year in the second quarter, due to a coronavirus-induced low base in the same quarter last year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Q3 GDP expands 6.5% y/y, largely matching forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Q3 GDP expands 6.5% y/y, largely matching forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-14 08:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SINGAPORE, Oct 14 (Reuters) - Singapore's economy grew 6.5% in the third quarter, preliminary official data showed on Thursday, broadly in line with economists' forecast.</p>\n<p>Economists polled by Reuters had expected an expansion of 6.6% year-on-year for the third quarter.</p>\n<p>Gross domestic product had jumped 15.2% year-on-year in the second quarter, due to a coronavirus-induced low base in the same quarter last year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175615162","content_text":"SINGAPORE, Oct 14 (Reuters) - Singapore's economy grew 6.5% in the third quarter, preliminary official data showed on Thursday, broadly in line with economists' forecast.\nEconomists polled by Reuters had expected an expansion of 6.6% year-on-year for the third quarter.\nGross domestic product had jumped 15.2% year-on-year in the second quarter, due to a coronavirus-induced low base in the same quarter last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":791,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820567156,"gmtCreate":1633404140378,"gmtModify":1633404306674,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820567156","repostId":"1121300578","repostType":4,"repost":{"id":"1121300578","pubTimestamp":1633395123,"share":"https://www.laohu8.com/m/news/1121300578?lang=&edition=full","pubTime":"2021-10-05 08:52","market":"us","language":"en","title":"SoFi Technologies stock dips after offering $1.1B of convertible notes","url":"https://stock-news.laohu8.com/highlight/detail?id=1121300578","media":"Seekingalpha","summary":"SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offeri","content":"<ul>\n <li>SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offering last week.</li>\n <li>In today's trading alone, the stock&nbsp;dips 1.8%&nbsp;in early afternoon trading.</li>\n <li>On Sept. 29, the company boosted the size of its debt offering to $1.1B from $750M. The notes can be converted into SoFi (SOFI) shares on or after April 15, 2026 until the trading day preceding Oct. 15, 2026.</li>\n <li>Shares of companies that issue convertible debt often decline as the conversion of the debt to shares would increase the number of shares outstanding, potentially diluting existing stockholders' stakes.</li>\n <li>Previously (Sept. 29),SoFi Technologies prices $1.1B of convertible notes offering</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SoFi Technologies stock dips after offering $1.1B of convertible notes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoFi Technologies stock dips after offering $1.1B of convertible notes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 08:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748268-sofi-technologies-stock-dips-after-offering-11b-of-convertible-notes><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offering last week.\nIn today's trading alone, the stock dips 1.8% in early afternoon trading.\nOn Sept. 29,...</p>\n\n<a href=\"https://seekingalpha.com/news/3748268-sofi-technologies-stock-dips-after-offering-11b-of-convertible-notes\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOFI":"SoFi Technologies Inc."},"source_url":"https://seekingalpha.com/news/3748268-sofi-technologies-stock-dips-after-offering-11b-of-convertible-notes","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121300578","content_text":"SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offering last week.\nIn today's trading alone, the stock dips 1.8% in early afternoon trading.\nOn Sept. 29, the company boosted the size of its debt offering to $1.1B from $750M. The notes can be converted into SoFi (SOFI) shares on or after April 15, 2026 until the trading day preceding Oct. 15, 2026.\nShares of companies that issue convertible debt often decline as the conversion of the debt to shares would increase the number of shares outstanding, potentially diluting existing stockholders' stakes.\nPreviously (Sept. 29),SoFi Technologies prices $1.1B of convertible notes offering","news_type":1},"isVote":1,"tweetType":1,"viewCount":634,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865841794,"gmtCreate":1632970083566,"gmtModify":1632970083724,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/865841794","repostId":"2171332039","repostType":4,"repost":{"id":"2171332039","pubTimestamp":1632967740,"share":"https://www.laohu8.com/m/news/2171332039?lang=&edition=full","pubTime":"2021-09-30 10:09","market":"us","language":"en","title":"Meme traders see red as heavily-shorted stocks grow scarcer and old names fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2171332039","media":"MarketWatch","summary":"Investors trading meme stocks spent Wednesday looking at a lot of red.\nThe unofficial meme-stock ind","content":"<p>Investors trading meme stocks spent Wednesday looking at a lot of red.</p>\n<p>The unofficial meme-stock index took a uniform pounding on Wednesday, with major names down significantly, and even a meme rotation into clean-energy names looked to slow down as retail investors found themselves playing an uneventful game of Whack-a-Mole trying to find heavily-shorted stocks to play for squeezes.</p>\n<p>But while the trading was ugly, retail investors took a macro thrill in signs that legal waters are getting choppy for their old frenemy Robinhood.</p>\n<p>Ur-memes like GameStop, AMC Entertainment, Blackberry&nbsp;and Koss&nbsp;all closed down to continue a rough weekly trend, and even new names like <a href=\"https://laohu8.com/S/CLNE\">Clean Energy Fuels Corp</a>&nbsp;and Canoo&nbsp;could not benefit from what seemed like early-week momentum of meme-stock traders plunging into renewable and green-energy names.</p>\n<p>But one name did manage to capitalize on that still-barely-breathing trend.</p>\n<p><a href=\"https://laohu8.com/S/CEI\">Camber Energy</a>&nbsp;closed up 6.2% after surging more than 30% in early trading. Camber, which saw a massive spike in social-media interest from retail traders on WallStreetBets, according to data from HypeEquity, also started the day as one of the most heavily shorted stocks on the market.</p>\n<p>Per a research note from Fintel, \"Raw short interest in Camber jumped from 6.1M shares as of August 31 to 24.4M shares on September 15, a colossal jump of 298%.\"</p>\n<p>For Camber, the old alchemy of heavy short interest and high social-media interest combined to give the natural-gas outfit big meme energy on Wednesday.</p>\n<p>That was not true for other heavily shorted names, however. Katapult Holdings Inc.&nbsp;fell 5%, e-commerce play Aterian&nbsp;plummeted 12.4%, and Vinco Ventures&nbsp;fell 3.2%.</p>\n<p>Even newly-listed hipster eyewear sweetheart Warby Parker failed to gain meme steam, giving up a midday surge to close up just 0.8%.</p>\n<p>But not all was dark and dreary on Reddit boards Wednesday, thanks to more potential legal schadenfreude coming from Robinhood HQ.</p>\n<p>In yet another class-action lawsuit filed on behalf of retail traders related to the zero-commission trading app's decision to halt trading on meme stocks on Jan. 28, at the height of the chaotic short squeeze, it was alleged that internal communications at Robinhood appear to indicate that the company's chief operating officer was unloading his shares in AMC just days before the app restricted trading on the stock.</p>\n<p>According to the filing, Jim Swartwout told colleagues via an internal chat on Jan. 26 \"I sold my AMC today.\"</p>\n<p>He followed up by warning fellow Robinhooders that \"FYI -- tomorrow morning we are moving GME to 100% -- so you are aware,\" apparently referring to the margin costs that Robinhood would be paying to hold the super-volatile stock on Jan. 27, one full day before the decision to restrict access was made.</p>\n<p>On Jan. 28, the company did restrict trading on both stocks, and others, after realizing it could no longer risk the margin costs.</p>\n<p>That move would have potentially protected Swartwout from taking losses on AMC shares that had surged almost 900% that month but would fall by 56% in the following days after Robinhood cut off access on its platform.</p>\n<p>The lawsuit was circulating widely by Wednesday afternoon, prompting a surge of subreddits dedicated to speculation on Swartwout's personal stock trading and a flurry of tweets casting suspicion on the purported stock dealings, and using them as yet more potential evidence to prove that anti-retail chicanery was a very real phenomenon at the height of January's squeeze.</p>\n<p>Neither Swartwout or Robinhood responded for comment on the lawsuit.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme traders see red as heavily-shorted stocks grow scarcer and old names fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme traders see red as heavily-shorted stocks grow scarcer and old names fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 10:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/meme-traders-see-red-as-heavily-shorted-stocks-grow-scarcer-and-old-names-fall-11632955167?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors trading meme stocks spent Wednesday looking at a lot of red.\nThe unofficial meme-stock index took a uniform pounding on Wednesday, with major names down significantly, and even a meme ...</p>\n\n<a href=\"https://www.marketwatch.com/story/meme-traders-see-red-as-heavily-shorted-stocks-grow-scarcer-and-old-names-fall-11632955167?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","WRBY":"Warby Parker Inc.","KOSS":"高斯电子","CLNE":"Clean Energy Fuels Corp","GOEV":"Canoo Inc.","ATER":"Aterian Inc.","BBIG":"Vinco Ventures, Inc.","AMC":"AMC院线","HOOD":"Robinhood","BB":"黑莓","KPLT":"Katapult Holdings, Inc.","CEI":"Camber Energy"},"source_url":"https://www.marketwatch.com/story/meme-traders-see-red-as-heavily-shorted-stocks-grow-scarcer-and-old-names-fall-11632955167?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2171332039","content_text":"Investors trading meme stocks spent Wednesday looking at a lot of red.\nThe unofficial meme-stock index took a uniform pounding on Wednesday, with major names down significantly, and even a meme rotation into clean-energy names looked to slow down as retail investors found themselves playing an uneventful game of Whack-a-Mole trying to find heavily-shorted stocks to play for squeezes.\nBut while the trading was ugly, retail investors took a macro thrill in signs that legal waters are getting choppy for their old frenemy Robinhood.\nUr-memes like GameStop, AMC Entertainment, Blackberry and Koss all closed down to continue a rough weekly trend, and even new names like Clean Energy Fuels Corp and Canoo could not benefit from what seemed like early-week momentum of meme-stock traders plunging into renewable and green-energy names.\nBut one name did manage to capitalize on that still-barely-breathing trend.\nCamber Energy closed up 6.2% after surging more than 30% in early trading. Camber, which saw a massive spike in social-media interest from retail traders on WallStreetBets, according to data from HypeEquity, also started the day as one of the most heavily shorted stocks on the market.\nPer a research note from Fintel, \"Raw short interest in Camber jumped from 6.1M shares as of August 31 to 24.4M shares on September 15, a colossal jump of 298%.\"\nFor Camber, the old alchemy of heavy short interest and high social-media interest combined to give the natural-gas outfit big meme energy on Wednesday.\nThat was not true for other heavily shorted names, however. Katapult Holdings Inc. fell 5%, e-commerce play Aterian plummeted 12.4%, and Vinco Ventures fell 3.2%.\nEven newly-listed hipster eyewear sweetheart Warby Parker failed to gain meme steam, giving up a midday surge to close up just 0.8%.\nBut not all was dark and dreary on Reddit boards Wednesday, thanks to more potential legal schadenfreude coming from Robinhood HQ.\nIn yet another class-action lawsuit filed on behalf of retail traders related to the zero-commission trading app's decision to halt trading on meme stocks on Jan. 28, at the height of the chaotic short squeeze, it was alleged that internal communications at Robinhood appear to indicate that the company's chief operating officer was unloading his shares in AMC just days before the app restricted trading on the stock.\nAccording to the filing, Jim Swartwout told colleagues via an internal chat on Jan. 26 \"I sold my AMC today.\"\nHe followed up by warning fellow Robinhooders that \"FYI -- tomorrow morning we are moving GME to 100% -- so you are aware,\" apparently referring to the margin costs that Robinhood would be paying to hold the super-volatile stock on Jan. 27, one full day before the decision to restrict access was made.\nOn Jan. 28, the company did restrict trading on both stocks, and others, after realizing it could no longer risk the margin costs.\nThat move would have potentially protected Swartwout from taking losses on AMC shares that had surged almost 900% that month but would fall by 56% in the following days after Robinhood cut off access on its platform.\nThe lawsuit was circulating widely by Wednesday afternoon, prompting a surge of subreddits dedicated to speculation on Swartwout's personal stock trading and a flurry of tweets casting suspicion on the purported stock dealings, and using them as yet more potential evidence to prove that anti-retail chicanery was a very real phenomenon at the height of January's squeeze.\nNeither Swartwout or Robinhood responded for comment on the lawsuit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861352238,"gmtCreate":1632462135924,"gmtModify":1632464336077,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"How long it will take?","listText":"How long it will take?","text":"How long it will take?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/861352238","repostId":"1199759162","repostType":4,"repost":{"id":"1199759162","pubTimestamp":1632454663,"share":"https://www.laohu8.com/m/news/1199759162?lang=&edition=full","pubTime":"2021-09-24 11:37","market":"us","language":"en","title":"If Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop","url":"https://stock-news.laohu8.com/highlight/detail?id=1199759162","media":"investorplace","summary":"Everyone loves to throw out long-term price targets on Bitcoin.\nARK Invest fund manager Cathie Wood ","content":"<p>Everyone loves to throw out long-term price targets on&nbsp;<b><u>Bitcoin</u></b>.</p>\n<p>ARK Invest fund manager&nbsp;<b>Cathie Wood</b>&nbsp;last week reiterated her firm’s call for Bitcoin to trend toward $500,000 per coin over the next several years.&nbsp;<b>Tyler Winklevoss</b>&nbsp;of Facebook fame and big crypto enthusiast has also pounded on the table about a $500,000 long-term price target for Bitcoin.</p>\n<p>Meanwhile, the relatively conservative analyst team over at&nbsp;<b>JPMorgan</b>&nbsp;has set a theoretical long-term price target for BTC of $130,000. A leaked&nbsp;<b>Citibank</b>&nbsp;report shows that the analysts over there think that the price could climb toward $300,000. Billionaire&nbsp;<b>Tim Draper</b>&nbsp;has gone on record multiple times saying Bitcoin prices will eclipse $250,000 by the end of 2022.</p>\n<p>And, in the most bullish call of them all,&nbsp;<b>Anthony Pompliano</b>– co-founder and partner at Morgan Creek Digital Assets – has said Bitcoin prices could soar to $1 million per token in the long run.</p>\n<p>Big numbers. Yes. But can Bitcoin really soar toward $200,000? $300,000? Even $500,000 or higher in the long run?</p>\n<p>Our short answer:<b><i>Yes.</i></b></p>\n<p>And the reasoning is pretty simple. Bitcoin is the digital version of gold. The gold market is an $11 trillion market. If Bitcoin gets that big, you’re talking an $11 trillion market on 21 million tokens, which implies a price per token of about $500,000.</p>\n<p>That’s the back-of-the-envelope reasoning and math behind the $500,000 price target.</p>\n<p>Of course, that model rests on some major assumptions. One, Bitcoin is the digital version of gold, and two, the Bitcoin market will be as big as the gold market.</p>\n<p><u>We think both are fair assumptions</u>.</p>\n<p>The modern value of gold derives from&nbsp;<b><i>scarcity</i></b>. Sure, maybe once upon a time, gold was used to barter for goods or used to make swords and shields. Not too long ago, it was used in some semiconductor chips.</p>\n<p>But those days are gone. Today, gold is used for nothing. Its value is in the fact that it has finite supply and, therefore, is a good store of value.</p>\n<p>The same is true for Bitcoin. In fact, it’s even more true for Bitcoin. There are, by definition, only 21 million Bitcoins in the world. There will never be more than that. Meanwhile, in the gold market, more gold mining efforts can always be put online to increase supply as demand increases.</p>\n<p>In other words, Bitcoin has more scarcity than gold and, therefore, isn’t just the digital version of gold – it is a digital and superior version of gold.</p>\n<p>Meanwhile, Bitcoin is&nbsp;<b><i>digital</i></b>, while gold is&nbsp;<b><i>physical</i></b>, and the whole world is pivoting toward digitization these days. Media is digital. Shopping is digital. Entertainment is digital. Communications are digital. Work is digital. Health is digital. Everything is digital.</p>\n<p>In that world, money will inevitably become digital, too. Indeed, that’s already happening. Venmo. Cash App. PayPal. SoFi. All of these digital money apps are soaring in usage right now, while the volume of cash transactions is plummeting.</p>\n<p>Therefore, Bitcoin is gold made for the modern world. You can’t send gold through a social media platform, or a streaming service, or use it buy a good online.&nbsp;<b>But you can use Bitcoin for that.</b></p>\n<p>To that extent, it’s easy to see why folks will ditch their physical store of value (gold) for a digital store of value (Bitcoin) – and why the Bitcoin market will become as big as (if not bigger than) the gold market.</p>\n<p>All in all, we think the fundamental reasoning underlying the Bitcoin market supports that Bitcoin prices will trend towards $500,000 in the long run.</p>\n<p>How long will it take to get there? No one really knows. Our best guess is about 10 years – and if so, you’re talking about an asset that will increase 10X in value in 10 years.</p>\n<p><u>That’s an</u>&nbsp;<u><b><i>amazing</i></b></u>&nbsp;<u>return</u>.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 11:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/09/if-bitcoin-really-is-digital-gold-then-500000-is-the-next-stop/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Everyone loves to throw out long-term price targets on Bitcoin.\nARK Invest fund manager Cathie Wood last week reiterated her firm’s call for Bitcoin to trend toward $500,000 per coin over the next ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/09/if-bitcoin-really-is-digital-gold-then-500000-is-the-next-stop/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/09/if-bitcoin-really-is-digital-gold-then-500000-is-the-next-stop/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199759162","content_text":"Everyone loves to throw out long-term price targets on Bitcoin.\nARK Invest fund manager Cathie Wood last week reiterated her firm’s call for Bitcoin to trend toward $500,000 per coin over the next several years. Tyler Winklevoss of Facebook fame and big crypto enthusiast has also pounded on the table about a $500,000 long-term price target for Bitcoin.\nMeanwhile, the relatively conservative analyst team over at JPMorgan has set a theoretical long-term price target for BTC of $130,000. A leaked Citibank report shows that the analysts over there think that the price could climb toward $300,000. Billionaire Tim Draper has gone on record multiple times saying Bitcoin prices will eclipse $250,000 by the end of 2022.\nAnd, in the most bullish call of them all, Anthony Pompliano– co-founder and partner at Morgan Creek Digital Assets – has said Bitcoin prices could soar to $1 million per token in the long run.\nBig numbers. Yes. But can Bitcoin really soar toward $200,000? $300,000? Even $500,000 or higher in the long run?\nOur short answer:Yes.\nAnd the reasoning is pretty simple. Bitcoin is the digital version of gold. The gold market is an $11 trillion market. If Bitcoin gets that big, you’re talking an $11 trillion market on 21 million tokens, which implies a price per token of about $500,000.\nThat’s the back-of-the-envelope reasoning and math behind the $500,000 price target.\nOf course, that model rests on some major assumptions. One, Bitcoin is the digital version of gold, and two, the Bitcoin market will be as big as the gold market.\nWe think both are fair assumptions.\nThe modern value of gold derives from scarcity. Sure, maybe once upon a time, gold was used to barter for goods or used to make swords and shields. Not too long ago, it was used in some semiconductor chips.\nBut those days are gone. Today, gold is used for nothing. Its value is in the fact that it has finite supply and, therefore, is a good store of value.\nThe same is true for Bitcoin. In fact, it’s even more true for Bitcoin. There are, by definition, only 21 million Bitcoins in the world. There will never be more than that. Meanwhile, in the gold market, more gold mining efforts can always be put online to increase supply as demand increases.\nIn other words, Bitcoin has more scarcity than gold and, therefore, isn’t just the digital version of gold – it is a digital and superior version of gold.\nMeanwhile, Bitcoin is digital, while gold is physical, and the whole world is pivoting toward digitization these days. Media is digital. Shopping is digital. Entertainment is digital. Communications are digital. Work is digital. Health is digital. Everything is digital.\nIn that world, money will inevitably become digital, too. Indeed, that’s already happening. Venmo. Cash App. PayPal. SoFi. All of these digital money apps are soaring in usage right now, while the volume of cash transactions is plummeting.\nTherefore, Bitcoin is gold made for the modern world. You can’t send gold through a social media platform, or a streaming service, or use it buy a good online. But you can use Bitcoin for that.\nTo that extent, it’s easy to see why folks will ditch their physical store of value (gold) for a digital store of value (Bitcoin) – and why the Bitcoin market will become as big as (if not bigger than) the gold market.\nAll in all, we think the fundamental reasoning underlying the Bitcoin market supports that Bitcoin prices will trend towards $500,000 in the long run.\nHow long will it take to get there? No one really knows. Our best guess is about 10 years – and if so, you’re talking about an asset that will increase 10X in value in 10 years.\nThat’s an amazing return.","news_type":1},"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":863036791,"gmtCreate":1632328884913,"gmtModify":1632801166254,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Should I?","listText":"Should I?","text":"Should I?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/863036791","repostId":"2169654289","repostType":4,"repost":{"id":"2169654289","pubTimestamp":1632321240,"share":"https://www.laohu8.com/m/news/2169654289?lang=&edition=full","pubTime":"2021-09-22 22:34","market":"us","language":"en","title":"Should You Buy Toast Stock? A Breakdown of Restaurant SaaS","url":"https://stock-news.laohu8.com/highlight/detail?id=2169654289","media":"Motley Fool","summary":"Toast is launching its IPO this week. The restaurant industry is being disrupted by innovation and digital transformation. Which restaurant SaaS stock should be in your portfolio?","content":"<blockquote>\n <b>Toast is launching its IPO this week. The restaurant industry is being disrupted by innovation and digital transformation. Which restaurant SaaS stock should be in your portfolio?</b>\n</blockquote>\n<p>Toast is expected to begin trading on the New York Stock Exchange Wednesday, Sept. 22, under the ticker TOST. It will be the latest in a long list of technology companies that have gone public over the past couple of years. In a nutshell, restaurants can run on Toast. The company is a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-stop shop offering point of sale, contactless ordering, hardware, online ordering and delivery, marketing, payroll and team management, and more. Toast is laser focused on helping restaurants be successful.&nbsp;</p>\n<p>Toast has four revenue streams:</p>\n<ol>\n <li><b>Software-as-a-service:</b> Includes solutions for POS, back-of-the-house kitchen displays, invoice management, digital ordering and delivery, marketing, loyalty, and team management.</li>\n <li><b>Fintech: </b>Includes payments, transaction fees, and even loans.</li>\n <li><b>Hardware:</b> Toast sells terminals, tablets, handheld devices, and accessories.</li>\n <li><b>Professional services:</b> Includes installation and configuration.&nbsp;</li>\n</ol>\n<p>Toast competes with POS vendors such as <b>Lightspeed Commerce</b> (NYSE:LSPD) and <b>Square</b> (NYSE:SQ). Additionally, the company competes with <b>Olo</b> (NYSE:OLO) in online ordering and delivery. With that said, Toast and Olo also partner, and the solutions can be integrated using Olo Rails. Rails allow integration with food delivery apps such as <b>DoorDash</b> (NYSE:DASH), <b>Uber Eats</b> (NYSE:UBER), and GrubHub, which is formally&nbsp;<b>Just Eat Takeaway.com</b>&nbsp;(NASDAQ:GRUB)</p>\n<p>In today's video, I break down Toast's business and compare it with the companies mentioned above. I also do deep-dive analysis on Toast's financial metrics and offer my opinions on the stock and if I'm buying. Please watch the below video for more information, and don't forget to subscribe to the channel.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Toast Stock? A Breakdown of Restaurant SaaS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Toast Stock? A Breakdown of Restaurant SaaS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 22:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/should-you-buy-toast-stock-a-breakdown-of-restaura/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Toast is launching its IPO this week. The restaurant industry is being disrupted by innovation and digital transformation. Which restaurant SaaS stock should be in your portfolio?\n\nToast is expected ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/should-you-buy-toast-stock-a-breakdown-of-restaura/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QSR":"餐饮品牌国际","TOST":"Toast, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/should-you-buy-toast-stock-a-breakdown-of-restaura/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169654289","content_text":"Toast is launching its IPO this week. The restaurant industry is being disrupted by innovation and digital transformation. Which restaurant SaaS stock should be in your portfolio?\n\nToast is expected to begin trading on the New York Stock Exchange Wednesday, Sept. 22, under the ticker TOST. It will be the latest in a long list of technology companies that have gone public over the past couple of years. In a nutshell, restaurants can run on Toast. The company is a one-stop shop offering point of sale, contactless ordering, hardware, online ordering and delivery, marketing, payroll and team management, and more. Toast is laser focused on helping restaurants be successful. \nToast has four revenue streams:\n\nSoftware-as-a-service: Includes solutions for POS, back-of-the-house kitchen displays, invoice management, digital ordering and delivery, marketing, loyalty, and team management.\nFintech: Includes payments, transaction fees, and even loans.\nHardware: Toast sells terminals, tablets, handheld devices, and accessories.\nProfessional services: Includes installation and configuration. \n\nToast competes with POS vendors such as Lightspeed Commerce (NYSE:LSPD) and Square (NYSE:SQ). Additionally, the company competes with Olo (NYSE:OLO) in online ordering and delivery. With that said, Toast and Olo also partner, and the solutions can be integrated using Olo Rails. Rails allow integration with food delivery apps such as DoorDash (NYSE:DASH), Uber Eats (NYSE:UBER), and GrubHub, which is formally Just Eat Takeaway.com (NASDAQ:GRUB)\nIn today's video, I break down Toast's business and compare it with the companies mentioned above. I also do deep-dive analysis on Toast's financial metrics and offer my opinions on the stock and if I'm buying. Please watch the below video for more information, and don't forget to subscribe to the channel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860760511,"gmtCreate":1632214567033,"gmtModify":1632802026759,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Up somemore&nbsp;","listText":"Up somemore&nbsp;","text":"Up somemore","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860760511","repostId":"1160840483","repostType":4,"repost":{"id":"1160840483","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632214161,"share":"https://www.laohu8.com/m/news/1160840483?lang=&edition=full","pubTime":"2021-09-21 16:49","market":"us","language":"en","title":"U.S. Stock Futures Advance, Airline shares, Carnival stocks rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1160840483","media":"Tiger Newspress","summary":"(Update: Sept 20, 2021 at 04:49 a.m. ET)\n(Sept 21) U.S. Stock Futures Advance, Airline shares, Carni","content":"<p><i><b>(Update: Sept 20, 2021 at 04:49 a.m. ET)</b></i></p>\n<p>(Sept 21)&nbsp;U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.</p>\n<p><img src=\"https://static.tigerbbs.com/9607d4b938bceb5794ca0672738db43c\" tg-width=\"1230\" tg-height=\"507\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/492800aae703e8bd5f15daf33c8c038e\" tg-width=\"274\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Futures Advance, Airline shares, Carnival stocks rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Futures Advance, Airline shares, Carnival stocks rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-21 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><i><b>(Update: Sept 20, 2021 at 04:49 a.m. ET)</b></i></p>\n<p>(Sept 21)&nbsp;U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.</p>\n<p><img src=\"https://static.tigerbbs.com/9607d4b938bceb5794ca0672738db43c\" tg-width=\"1230\" tg-height=\"507\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/492800aae703e8bd5f15daf33c8c038e\" tg-width=\"274\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SPY":"标普500ETF",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160840483","content_text":"(Update: Sept 20, 2021 at 04:49 a.m. ET)\n(Sept 21) U.S. Stock Futures Advance, Airline shares, Carnival stocks rally.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860055686,"gmtCreate":1632111023245,"gmtModify":1632802761750,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Great, Nvidia!","listText":"Great, Nvidia!","text":"Great, Nvidia!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/860055686","repostId":"2168505605","repostType":4,"repost":{"id":"2168505605","pubTimestamp":1632107672,"share":"https://www.laohu8.com/m/news/2168505605?lang=&edition=full","pubTime":"2021-09-20 11:14","market":"us","language":"en","title":"3 Stocks to Add to Your Portfolio in a Market Pull-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2168505605","media":"Motley Fool","summary":"These great stocks are just a little too expensive to be perfect investments right now.","content":"<p>Stocks are expensive right now, with the <b>S&amp;P 500</b> price-to-earnings ratio at its highest level since the dot-com bubble. That doesn't mean that investors should be selling all their stocks and waiting for the next crash. It could be a while until a correction occurs, and that sort of strategy would have caused you to miss out on the past year of market growth.</p>\n<p>Still, some shrewd investors have built more defensive portfolios and are waiting for a pull-back to scoop up great companies that happen to have aggressive valuations right now. These three stocks are great opportunities that you should consider if they get any cheaper.</p>\n<h2>Nvidia</h2>\n<p><b>Nvidia</b> (NASDAQ:NVDA) is a rockstar tech stock with outstanding growth catalysts, and it's returned more than 230% since the pandemic market bottom in March 2020.</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/e4d03dae188b51897bf508dc9b12336c.png\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>NVDA data by YCharts</span></p>\n<p>Nvidia is the global market leader in PC graphics processor units (GPU), with 83% market share. The company supplies microchips that are essential for gaming, high-performance video, and other applications that require more advanced visual hardware. The global video game market is expected to grow more than 12% annually over the next five years, and high-resolution video content continues to become a preferred media for consumers. Those factors alone provide catalysts for Nvidia for the foreseeable future.</p>\n<p>However, Nvidia's opportunity isn't limited to gaming and personal computing. The company's chips have important applications in data centers, the automotive and autonomous vehicle industry, artificial intelligence and automation technology, and 5G network infrastructure. Connection to those trends provides an even more enticing growth opportunity.</p>\n<p>What's the catch here? Nvidia is expensive. Its forward price-to-earnings ratio of 55 is high relative to most other semiconductor stocks, and it's substantially higher than Nvidia's own recent historical levels. Even the PEG ratio, which takes into account the company's bullish growth forecast, indicates an expensive-looking stock.</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/a51764bc0c3216578fb6c349d060cc6d.png\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>NVDA P/E Ratio (Forward 1y) data by YCharts</span></p>\n<p>Overall, it seems that Nvidia is a great stock to own, but there might be less expensive alternatives that can deliver better fundamentals for the price. If there's a market pull-back anytime soon, Nvidia should be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the first stocks to consider at a lower price.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32358a5a70714295cef5e46d939c1d3e\" tg-width=\"700\" tg-height=\"404\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Chipotle</h2>\n<p><b>Chipotle Mexican Grill</b> (NYSE:CMG) is a chain of well-known, fast-casual restaurants. The company has managed to endure a handful of scandals and an unprecedented pandemic, and it just keeps on growing. The chain's perceived value, nutrition, quality, and convenience clearly resonate with consumers. With double-digit growth forecast for this year and next, it doesn't seem like there's any reason to expect Chipotle to falter soon.</p>\n<p>Chipotle has plenty of avenues for continued growth that excite investors. It has fewer than 2,900 locations, less than half of its sales are from its digital channel, and delivery services only produce 1% of total revenue. The company produces substantial cash flow, and the only debt on its balance sheet is related to operating lease obligations, not loans. That limits financial risk and means that Chipotle could easily source capital for growth if the need arose.</p>\n<p>Once again, the issue here is really about valuation. Chipotle has often attracted aggressive valuation multiples, and its 56 forward P/E ratio seems more characteristic of a tech company than an established restaurant chain. Its enterprise-value-to-EBITDA ratio of 50 indicates that it's not a situation in which earnings per share misrepresent true profits. Chipotle is simply expensive to own. If the market gives you an opportunity to scoop up some shares at a more attractive price, it's worth consideration.</p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p><b>Visa</b> (NYSE:V) is a household name with a brand that's nearly synonymous with credit and debit cards. People see that logo every day, and it's also featured on the front doors of countless restaurants and retailers that accept Visa cards. There's more going on under the surface here, too, and this company offers some exposure to a wider fintech revolution that's been occurring.</p>\n<p>Visa is really a payment processing network with global reach, rather than a credit card supplier. This is a rapidly evolving landscape with the likes of <b>Square</b> (NYSE:SQ), <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> (NASDAQ:PYPL), countless ambitious start-ups, and various blockchain solutions springing up to bring efficiency and security to digital payments and transfers.</p>\n<p>Visa remains competitive by making acquisitions and creating partnerships with innovators that might otherwise turn into competitors. Regulators blocked its acquisition of Plaid, and Visa pivoted by purchasing the B2B cross-border payment platform Currencycloud and Tink, a European open-banking platform for consumers.</p>\n<p>Visa offers a compelling business narrative, but its value as an investment is a bit less straightforward. It's hard to consider this a value stock with a forward P/E ratio of 30.6 and a 0.6% dividend yield. Like many other stocks, Visa is near the high end of its recent range for the P/E ratio.</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/e6f09aebc95eb66f909e97fb08b12336.png\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>V Normalized PE Ratio (Annual) data by YCharts</span></p>\n<p>On the other hand, Visa is mature compared to other fintech stocks and doesn't have quite the same growth prospects. It's also in a tough spot as the incumbent power in an industry that's undergoing rapid evolution. If we have a market correction, Visa would suddenly look a lot better as a value investment with more upside than most. If the stock's price dips around 15%, its PEG ratio would creep toward 1.5. At that valuation, I would buy Visa hand over fist as a cash flow generator with uncommon growth potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Add to Your Portfolio in a Market Pull-Back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Add to Your Portfolio in a Market Pull-Back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 11:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/19/3-stocks-to-add-to-your-portfolio-in-a-market-pull/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks are expensive right now, with the S&P 500 price-to-earnings ratio at its highest level since the dot-com bubble. That doesn't mean that investors should be selling all their stocks and waiting ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/19/3-stocks-to-add-to-your-portfolio-in-a-market-pull/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMG":"墨式烧烤","V":"Visa","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/09/19/3-stocks-to-add-to-your-portfolio-in-a-market-pull/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168505605","content_text":"Stocks are expensive right now, with the S&P 500 price-to-earnings ratio at its highest level since the dot-com bubble. That doesn't mean that investors should be selling all their stocks and waiting for the next crash. It could be a while until a correction occurs, and that sort of strategy would have caused you to miss out on the past year of market growth.\nStill, some shrewd investors have built more defensive portfolios and are waiting for a pull-back to scoop up great companies that happen to have aggressive valuations right now. These three stocks are great opportunities that you should consider if they get any cheaper.\nNvidia\nNvidia (NASDAQ:NVDA) is a rockstar tech stock with outstanding growth catalysts, and it's returned more than 230% since the pandemic market bottom in March 2020.\nNVDA data by YCharts\nNvidia is the global market leader in PC graphics processor units (GPU), with 83% market share. The company supplies microchips that are essential for gaming, high-performance video, and other applications that require more advanced visual hardware. The global video game market is expected to grow more than 12% annually over the next five years, and high-resolution video content continues to become a preferred media for consumers. Those factors alone provide catalysts for Nvidia for the foreseeable future.\nHowever, Nvidia's opportunity isn't limited to gaming and personal computing. The company's chips have important applications in data centers, the automotive and autonomous vehicle industry, artificial intelligence and automation technology, and 5G network infrastructure. Connection to those trends provides an even more enticing growth opportunity.\nWhat's the catch here? Nvidia is expensive. Its forward price-to-earnings ratio of 55 is high relative to most other semiconductor stocks, and it's substantially higher than Nvidia's own recent historical levels. Even the PEG ratio, which takes into account the company's bullish growth forecast, indicates an expensive-looking stock.\nNVDA P/E Ratio (Forward 1y) data by YCharts\nOverall, it seems that Nvidia is a great stock to own, but there might be less expensive alternatives that can deliver better fundamentals for the price. If there's a market pull-back anytime soon, Nvidia should be one of the first stocks to consider at a lower price.\nImage source: Getty Images.\nChipotle\nChipotle Mexican Grill (NYSE:CMG) is a chain of well-known, fast-casual restaurants. The company has managed to endure a handful of scandals and an unprecedented pandemic, and it just keeps on growing. The chain's perceived value, nutrition, quality, and convenience clearly resonate with consumers. With double-digit growth forecast for this year and next, it doesn't seem like there's any reason to expect Chipotle to falter soon.\nChipotle has plenty of avenues for continued growth that excite investors. It has fewer than 2,900 locations, less than half of its sales are from its digital channel, and delivery services only produce 1% of total revenue. The company produces substantial cash flow, and the only debt on its balance sheet is related to operating lease obligations, not loans. That limits financial risk and means that Chipotle could easily source capital for growth if the need arose.\nOnce again, the issue here is really about valuation. Chipotle has often attracted aggressive valuation multiples, and its 56 forward P/E ratio seems more characteristic of a tech company than an established restaurant chain. Its enterprise-value-to-EBITDA ratio of 50 indicates that it's not a situation in which earnings per share misrepresent true profits. Chipotle is simply expensive to own. If the market gives you an opportunity to scoop up some shares at a more attractive price, it's worth consideration.\nVisa\nVisa (NYSE:V) is a household name with a brand that's nearly synonymous with credit and debit cards. People see that logo every day, and it's also featured on the front doors of countless restaurants and retailers that accept Visa cards. There's more going on under the surface here, too, and this company offers some exposure to a wider fintech revolution that's been occurring.\nVisa is really a payment processing network with global reach, rather than a credit card supplier. This is a rapidly evolving landscape with the likes of Square (NYSE:SQ), PayPal (NASDAQ:PYPL), countless ambitious start-ups, and various blockchain solutions springing up to bring efficiency and security to digital payments and transfers.\nVisa remains competitive by making acquisitions and creating partnerships with innovators that might otherwise turn into competitors. Regulators blocked its acquisition of Plaid, and Visa pivoted by purchasing the B2B cross-border payment platform Currencycloud and Tink, a European open-banking platform for consumers.\nVisa offers a compelling business narrative, but its value as an investment is a bit less straightforward. It's hard to consider this a value stock with a forward P/E ratio of 30.6 and a 0.6% dividend yield. Like many other stocks, Visa is near the high end of its recent range for the P/E ratio.\nV Normalized PE Ratio (Annual) data by YCharts\nOn the other hand, Visa is mature compared to other fintech stocks and doesn't have quite the same growth prospects. It's also in a tough spot as the incumbent power in an industry that's undergoing rapid evolution. If we have a market correction, Visa would suddenly look a lot better as a value investment with more upside than most. If the stock's price dips around 15%, its PEG ratio would creep toward 1.5. At that valuation, I would buy Visa hand over fist as a cash flow generator with uncommon growth potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":60,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887940095,"gmtCreate":1631964571917,"gmtModify":1632805057856,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Yeah, seems like.","listText":"Yeah, seems like.","text":"Yeah, seems like.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887940095","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":12,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817405174,"gmtCreate":1630978536898,"gmtModify":1632904826358,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Wow. Good.","listText":"Wow. Good.","text":"Wow. Good.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/817405174","repostId":"1151344698","repostType":4,"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814327435,"gmtCreate":1630768308127,"gmtModify":1632905975890,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Wow… meme","listText":"Wow… meme","text":"Wow… meme","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814327435","repostId":"1189766406","repostType":4,"isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818203381,"gmtCreate":1630409110843,"gmtModify":1633678289687,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Omg!!!","listText":"Omg!!!","text":"Omg!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818203381","repostId":"2163319158","repostType":4,"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811890494,"gmtCreate":1630305302618,"gmtModify":1704958117551,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Pinduoduo and JD, yeah!","listText":"Pinduoduo and JD, yeah!","text":"Pinduoduo and JD, yeah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/811890494","repostId":"1129600310","repostType":4,"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813942250,"gmtCreate":1630125313470,"gmtModify":1704956337419,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Rocket again","listText":"Rocket again","text":"Rocket again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/813942250","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://www.laohu8.com/m/news/1199074003?lang=&edition=full","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835100600,"gmtCreate":1629690134500,"gmtModify":1633683147927,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3578292165234013","authorIdStr":"3578292165234013"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835100600","repostId":"1197131256","repostType":4,"isVote":1,"tweetType":1,"viewCount":49,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":801926264,"gmtCreate":1627480263658,"gmtModify":1633764612101,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Up some more&nbsp;","listText":"Up some more&nbsp;","text":"Up some more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/801926264","repostId":"1155605072","repostType":4,"isVote":1,"tweetType":1,"viewCount":81,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181597894,"gmtCreate":1623400461118,"gmtModify":1634033740447,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Will Pfizer price up then?&nbsp;","listText":"Will Pfizer price up then?&nbsp;","text":"Will Pfizer price up then?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/181597894","repostId":"2142274300","repostType":4,"repost":{"id":"2142274300","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623398404,"share":"https://www.laohu8.com/m/news/2142274300?lang=&edition=full","pubTime":"2021-06-11 16:00","market":"us","language":"en","title":"Thailand books 20 mln doses of Pfizer-BioNTech COVID-19 vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2142274300","media":"Reuters","summary":"BANGKOK, June 11 (Reuters) - Thailand has signed a purchase order for 20 million doses of the COVID-","content":"<p>BANGKOK, June 11 (Reuters) - Thailand has signed a purchase order for 20 million doses of the COVID-19 vaccine develop by Pfizer and BioNTech to be delivered before the end of this year, its health minister said.</p>\n<p>Details of the deal, delivery timeframe and the vaccine's approval by the Food and Drug Administration would be worked out in about a month, Thai Health Minister Anutin Charnvirakul said on Thursday.</p>\n<p>Thailand also plan to buy 5 million doses of Johnson &amp; Johnson's single-shot vaccine within this year, Anutin said.</p>\n<p>Thailand is racing to secure vaccines for its mass immunisation campaign that started on Monday, two months after it was hit by its biggest coronavirus outbreak so far, driven by highly contagious variants.</p>\n<p>The programme had relied heavily on its reserved 61 million doses of locally-made AstraZeneca vaccines, but the government has tried to diversify its sources to meet its target of acquiring 100 million doses by year-end.</p>\n<p>About 4.1 million of Thailand's more than 66 million people have so far received a first dose of a COVID-19 vaccine.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Thailand books 20 mln doses of Pfizer-BioNTech COVID-19 vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThailand books 20 mln doses of Pfizer-BioNTech COVID-19 vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-11 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BANGKOK, June 11 (Reuters) - Thailand has signed a purchase order for 20 million doses of the COVID-19 vaccine develop by Pfizer and BioNTech to be delivered before the end of this year, its health minister said.</p>\n<p>Details of the deal, delivery timeframe and the vaccine's approval by the Food and Drug Administration would be worked out in about a month, Thai Health Minister Anutin Charnvirakul said on Thursday.</p>\n<p>Thailand also plan to buy 5 million doses of Johnson &amp; Johnson's single-shot vaccine within this year, Anutin said.</p>\n<p>Thailand is racing to secure vaccines for its mass immunisation campaign that started on Monday, two months after it was hit by its biggest coronavirus outbreak so far, driven by highly contagious variants.</p>\n<p>The programme had relied heavily on its reserved 61 million doses of locally-made AstraZeneca vaccines, but the government has tried to diversify its sources to meet its target of acquiring 100 million doses by year-end.</p>\n<p>About 4.1 million of Thailand's more than 66 million people have so far received a first dose of a COVID-19 vaccine.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142274300","content_text":"BANGKOK, June 11 (Reuters) - Thailand has signed a purchase order for 20 million doses of the COVID-19 vaccine develop by Pfizer and BioNTech to be delivered before the end of this year, its health minister said.\nDetails of the deal, delivery timeframe and the vaccine's approval by the Food and Drug Administration would be worked out in about a month, Thai Health Minister Anutin Charnvirakul said on Thursday.\nThailand also plan to buy 5 million doses of Johnson & Johnson's single-shot vaccine within this year, Anutin said.\nThailand is racing to secure vaccines for its mass immunisation campaign that started on Monday, two months after it was hit by its biggest coronavirus outbreak so far, driven by highly contagious variants.\nThe programme had relied heavily on its reserved 61 million doses of locally-made AstraZeneca vaccines, but the government has tried to diversify its sources to meet its target of acquiring 100 million doses by year-end.\nAbout 4.1 million of Thailand's more than 66 million people have so far received a first dose of a COVID-19 vaccine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142160087,"gmtCreate":1626136867749,"gmtModify":1633929811259,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Amazon price is so high now, the price will still go up?","listText":"Amazon price is so high now, the price will still go up?","text":"Amazon price is so high now, the price will still go up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/142160087","repostId":"1125747733","repostType":4,"repost":{"id":"1125747733","pubTimestamp":1626136138,"share":"https://www.laohu8.com/m/news/1125747733?lang=&edition=full","pubTime":"2021-07-13 08:28","market":"us","language":"en","title":"3 Unstoppable Stocks to Buy Instead of AMC","url":"https://stock-news.laohu8.com/highlight/detail?id=1125747733","media":"Motley Fool","summary":"Key Points\n\nAMC could continue to perform well over the near term, but its long-term growth prospect","content":"<p><b>Key Points</b></p>\n<ul>\n <li>AMC could continue to perform well over the near term, but its long-term growth prospects are less certain.</li>\n <li>Several other stocks are poised to deliver stronger long-term growth by capitalizing on unstoppable trends.</li>\n</ul>\n<p></p>\n<p>If you're looking for trash talk about&nbsp;<b>AMC Entertainment</b>(NYSE:AMC), you won't find it here. I fully expect AMC's business to rebound significantly this year and into 2022. It's possible that the high-flying stock could still perform pretty well over the near term.</p>\n<p>However, long-term investors must focus on -- unsurprisingly -- the long term. And it's the long term where things get murkier for AMC, in my view. I'm doubtful that the company will have strong and sustainable growth after it fully recovers from the effects of the pandemic.</p>\n<p>On the other hand, there are other companies that should have tremendous long-term prospects. These businesses will not just profit as COVID-19 concerns hopefully diminish; they're built to continue growing for years to come.&nbsp;Here are three unstoppable stocks to buy instead of AMC.</p>\n<p><b>Amazon.com</b></p>\n<p>What are technologies that will almost certainly be even more widely adopted in the future? I'd put artificial intelligence (AI), e-commerce, self-driving cars, streaming TV, and telehealth on the list, for sure.&nbsp;<b>Amazon.com</b>(NASDAQ:AMZN)is targeting each of these areas.</p>\n<p>\"Targeting\" is really too weak of a word to use with respect to Amazon's e-commerce business. The company reigns as the 800-pound gorilla in e-commerce with online sales of $52.9 billion in the first quarter, up 41% year over year. But e-commerce comprised only 13.4% of total U.S. retail sales in Q1, giving Amazon plenty of opportunities for growth.</p>\n<p>Amazon's most obvious AI product is its Alexa virtual assistant. However, the company is probably making the most impact on AI adoption with its Amazon Web Services (AWS) cloud hosting unit. Nearly 90% of AI deep learning projects on the cloud are hosted on AWS.</p>\n<p>Perhaps the best reason to invest in Amazon is that it has a wide range of growth opportunities. One that I'm especially watching closely is the company's move into healthcare. Amazon has already launched an online pharmacy and is ina good position to become a leader in telehealthwith its new Amazon Care service.</p>\n<p><b>Brookfield Renewable</b></p>\n<p>Another unstoppable trend that could make long-term investors a lot of money is the increased use of renewable energy sources. Countries across the world have established ambitious goals for reducing carbon emissions. So have major corporations (including Amazon).&nbsp;<b>Brookfield Renewable</b>(NYSE:BEP)(NYSE:BEPC)stands out as one of the bestrenewable energy stocksto buy.</p>\n<p>Brookfield Renewable operates nearly 6,000 power generation facilities across four continents with a combined capacity of roughly 21,000 megawatts. Around 62% of the company's capacity comes from hydroelectric power, but Brookfield Renewable is increasing its wind and solar portfolio.</p>\n<p>The company thinks it can deliver annual total returns of close to 15% over the long term. That goal seems attainable considering that Brookfield Renewable has achieved an 18% average annual total return over the last two decades and has a development pipeline that could more than double its current capacity.</p>\n<p>Brookfield Renewable also offers something that neither AMC nor Amazon do -- a strong dividend. Its dividend yield currently stands at close to 3%. The company has increased its distribution by a compound annual growth rate of 6% since 2000.</p>\n<p><b>Intuitive Surgical</b></p>\n<p>There's another unstoppable trend that you probably don't think about very much. The use of robotic surgical systems continues to grow.&nbsp;<b>Intuitive Surgical</b>(NASDAQ:ISRG)is the indisputable leader in this market.</p>\n<p>Like AMC, Intuitive Surgical faced headwinds from the COVID-19 pandemic although its challenges weren't nearly as great as those of the theater chain. The good news for Intuitive is that procedure volumes continue to rebound strongly.</p>\n<p>Just how much can Intuitive grow? The company estimates that around 6 million procedures are performed annually where it already has products and regulatory clearances. In 2020, Intuitive's robotic systems were used in a little over 1.2 million procedures.</p>\n<p>Even better, Intuitive Surgical continues to introduce new products that expand the types of procedures for which robotic assistance can be used. Close to 20 million soft tissue surgeries are performed each year. Over time, Intuitive could be in a position to target all of these procedures.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks to Buy Instead of AMC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks to Buy Instead of AMC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-13 08:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/12/3-unstoppable-stocks-to-buy-instead-of-amc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nAMC could continue to perform well over the near term, but its long-term growth prospects are less certain.\nSeveral other stocks are poised to deliver stronger long-term growth by ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/12/3-unstoppable-stocks-to-buy-instead-of-amc/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司","BEPC":"Brookfield Renewable Corp.","AMZN":"亚马逊","BEP":"Brookfield Renewable Partners LP"},"source_url":"https://www.fool.com/investing/2021/07/12/3-unstoppable-stocks-to-buy-instead-of-amc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125747733","content_text":"Key Points\n\nAMC could continue to perform well over the near term, but its long-term growth prospects are less certain.\nSeveral other stocks are poised to deliver stronger long-term growth by capitalizing on unstoppable trends.\n\n\nIf you're looking for trash talk about AMC Entertainment(NYSE:AMC), you won't find it here. I fully expect AMC's business to rebound significantly this year and into 2022. It's possible that the high-flying stock could still perform pretty well over the near term.\nHowever, long-term investors must focus on -- unsurprisingly -- the long term. And it's the long term where things get murkier for AMC, in my view. I'm doubtful that the company will have strong and sustainable growth after it fully recovers from the effects of the pandemic.\nOn the other hand, there are other companies that should have tremendous long-term prospects. These businesses will not just profit as COVID-19 concerns hopefully diminish; they're built to continue growing for years to come. Here are three unstoppable stocks to buy instead of AMC.\nAmazon.com\nWhat are technologies that will almost certainly be even more widely adopted in the future? I'd put artificial intelligence (AI), e-commerce, self-driving cars, streaming TV, and telehealth on the list, for sure. Amazon.com(NASDAQ:AMZN)is targeting each of these areas.\n\"Targeting\" is really too weak of a word to use with respect to Amazon's e-commerce business. The company reigns as the 800-pound gorilla in e-commerce with online sales of $52.9 billion in the first quarter, up 41% year over year. But e-commerce comprised only 13.4% of total U.S. retail sales in Q1, giving Amazon plenty of opportunities for growth.\nAmazon's most obvious AI product is its Alexa virtual assistant. However, the company is probably making the most impact on AI adoption with its Amazon Web Services (AWS) cloud hosting unit. Nearly 90% of AI deep learning projects on the cloud are hosted on AWS.\nPerhaps the best reason to invest in Amazon is that it has a wide range of growth opportunities. One that I'm especially watching closely is the company's move into healthcare. Amazon has already launched an online pharmacy and is ina good position to become a leader in telehealthwith its new Amazon Care service.\nBrookfield Renewable\nAnother unstoppable trend that could make long-term investors a lot of money is the increased use of renewable energy sources. Countries across the world have established ambitious goals for reducing carbon emissions. So have major corporations (including Amazon). Brookfield Renewable(NYSE:BEP)(NYSE:BEPC)stands out as one of the bestrenewable energy stocksto buy.\nBrookfield Renewable operates nearly 6,000 power generation facilities across four continents with a combined capacity of roughly 21,000 megawatts. Around 62% of the company's capacity comes from hydroelectric power, but Brookfield Renewable is increasing its wind and solar portfolio.\nThe company thinks it can deliver annual total returns of close to 15% over the long term. That goal seems attainable considering that Brookfield Renewable has achieved an 18% average annual total return over the last two decades and has a development pipeline that could more than double its current capacity.\nBrookfield Renewable also offers something that neither AMC nor Amazon do -- a strong dividend. Its dividend yield currently stands at close to 3%. The company has increased its distribution by a compound annual growth rate of 6% since 2000.\nIntuitive Surgical\nThere's another unstoppable trend that you probably don't think about very much. The use of robotic surgical systems continues to grow. Intuitive Surgical(NASDAQ:ISRG)is the indisputable leader in this market.\nLike AMC, Intuitive Surgical faced headwinds from the COVID-19 pandemic although its challenges weren't nearly as great as those of the theater chain. The good news for Intuitive is that procedure volumes continue to rebound strongly.\nJust how much can Intuitive grow? The company estimates that around 6 million procedures are performed annually where it already has products and regulatory clearances. In 2020, Intuitive's robotic systems were used in a little over 1.2 million procedures.\nEven better, Intuitive Surgical continues to introduce new products that expand the types of procedures for which robotic assistance can be used. Close to 20 million soft tissue surgeries are performed each year. Over time, Intuitive could be in a position to target all of these procedures.","news_type":1},"isVote":1,"tweetType":1,"viewCount":252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":873175199,"gmtCreate":1636900751953,"gmtModify":1636900756497,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Good, continue to hold.","listText":"Good, continue to hold.","text":"Good, continue to hold.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873175199","repostId":"1103944030","repostType":4,"repost":{"id":"1103944030","pubTimestamp":1636857439,"share":"https://www.laohu8.com/m/news/1103944030?lang=&edition=full","pubTime":"2021-11-14 10:37","market":"us","language":"en","title":"These are the next three mega-cap tech stocks you’ll be hearing more about","url":"https://stock-news.laohu8.com/highlight/detail?id=1103944030","media":"MarketWatch","summary":"AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is","content":"<p>AMD is among companies poised to eclipse $200 billion in market value</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8977785546ccb691b11117bea0aa1480\" tg-width=\"1320\" tg-height=\"742\" referrerpolicy=\"no-referrer\"><span>AMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images</span></p>\n<p>As technology stocks have led the market for the better part of a dozen years, there are now 15 companies in the sector that have risen to mega-cap status — those valued at $200 billion or more.</p>\n<p>Five are valued at more than $1 trillion, including electric-vehicle maker Tesla,which I consider a tech company.</p>\n<p>Bets have been placed on which companies will rise to a trillion next, with Meta Platforms&nbsp;— aka Facebook — at the top of most lists and&nbsp;Nvidia,sitting on top of mine as a call I made 14 months ago.</p>\n<p>Perhaps harder than rising from north of half a trillion to a trillion is rising from less than&nbsp;$200 billion&nbsp;to break the threshold into mega-cap status.</p>\n<p>However, a few companies look destined for this outcome precisely, and I believe three have an incredibly compelling case to get there within the next 12 to 18 months — if not sooner.</p>\n<p><b>1. ServiceNow:</b>&nbsp;ServiceNow&nbsp;has been on an incredible run for more than a decade. From 2010 to 2020, revenues grew at a 59.2% average annual rate, while its stock rose at 44% a year. The company finished the 2020 calendar year at about $4.5 billion in revenue, and its trailing 12 months have surged close to $5.5 billion.</p>\n<p>The company now has more than 1,266 customers with a million or more dollars in recurring revenue, and is seeing this number grow at a substantial rate, including 25% in its most recent quarter.</p>\n<p>Beyond the numbers, the company’s technology, which enables companies to automate and implement digital workflows, continues to prove robust and best of breed. The most recent release of its Rome platform, three additional acquisitions to expand its portfolio and a deepened partnership with Microsoft&nbsp;are just a few recent highlights that provide the company a pathway to growth that should accelerate based on trends including app modernization, hybrid work, workflow automation, and even enterprise ESG initiatives.</p>\n<p>It’s hard to see ServiceNow not providing the robust growth that will take its market cap above $200 billion.&nbsp;The company’s market value is about $138 billion as of Monday.</p>\n<p><b>2. Qualcomm:</b>Qualcomm’s&nbsp;strong earnings report released last week — earnings per share jumped 76% year over year and revenue rose 43% — helped drive the stock to over $160 from the low $120s in mid-October.</p>\n<p>Consequently, that took the company’s market cap from about $145 billion to over $180 billion in just a matter of days. It serves as a timely reminder of how quickly a tech company in the right markets can produce momentum.</p>\n<p>Qualcomm, while best known as a chip provider for mobile handsets, is rapidly becoming a much bigger force in many categories, including the internet of things (IoT), automotive and wireless RFFE. With IoT and wireless RFFE surpassing a billion dollars a quarter in revenue, and automotive reaching nearly a billion in annual revenue with a $10 billion design pipeline, the company is becoming increasingly diversified. Thirty-eight percent of revenue in its QCT semiconductor business is now unrelated to handsets.</p>\n<p>Perhaps these adjacent business successes alone could catapult the company’s market value to over $200 billion, but what Qualcomm also has going for it is an undisputable global market leadership in 5G, which will continue to accelerate its handset business, as well as all of its adjacencies and massive licensing business.</p>\n<p><b>3. AMD:</b>&nbsp;I’ve been critical at times of Advanced Micro Devices,and sometimes you have to lean into calls you get wrong. While Intel&nbsp;under new CEO Pat Gelsinger shows more ambition and clear direction, AMD under Lisa Su has been on an absolute tear.</p>\n<p>In August, Mercury Research reported that AMD’s 22.5% x86 market share was its best in 14 years. With 4.2% year-over-year market share growth in its second quarter and another 54% overall revenue growth in the third quarter, the company’s market share gains look likely to continue.</p>\n<p>While I do think Intel is quickly patching its gaps and going to be a much more robust competitor, I believe the overall demand for CPUs (central processing units), GPUs (graphics processing units) and FPGAs (field-programmable gate arrays) will drive a larger total addressable market, and AMD’s going to grow revenues even if market share gains level off.</p>\n<p>Speaking of FPGA’s, the impending Xilinx deal, which I believe will gain regulatory approval, hasn’t been accounted for by many investors.</p>\n<p>AMD’s market value rose to over $180 billion Monday after the stock surged more than 10%. The company on Monday announced a range of news, including the fact that Meta will use its Epyc processors in its data center computers.</p>\n<p>After those three, I would add Micron Technology&nbsp;as an honorable mention. The company sits at closer to $85 billion in market cap. Still, as our thirst for compute continues to grow, the need for memory technology will scale dramatically, making Micron a significant beneficiary along with the likes of Samsung, which already sits well inside mega-cap territory.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the next three mega-cap tech stocks you’ll be hearing more about</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the next three mega-cap tech stocks you’ll be hearing more about\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-14 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images\nAs technology stocks have led the market for the better part of ...</p>\n\n<a href=\"https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NOW":"ServiceNow","NVDA":"英伟达","AMD":"美国超微公司","QCOM":"高通"},"source_url":"https://www.marketwatch.com/story/these-are-the-next-three-mega-cap-tech-stocks-youll-be-hearing-more-about-11636392083?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103944030","content_text":"AMD is among companies poised to eclipse $200 billion in market value\nAMD Chief Executive Lisa Su is seen in 2017. AFP via Getty Images\nAs technology stocks have led the market for the better part of a dozen years, there are now 15 companies in the sector that have risen to mega-cap status — those valued at $200 billion or more.\nFive are valued at more than $1 trillion, including electric-vehicle maker Tesla,which I consider a tech company.\nBets have been placed on which companies will rise to a trillion next, with Meta Platforms — aka Facebook — at the top of most lists and Nvidia,sitting on top of mine as a call I made 14 months ago.\nPerhaps harder than rising from north of half a trillion to a trillion is rising from less than $200 billion to break the threshold into mega-cap status.\nHowever, a few companies look destined for this outcome precisely, and I believe three have an incredibly compelling case to get there within the next 12 to 18 months — if not sooner.\n1. ServiceNow: ServiceNow has been on an incredible run for more than a decade. From 2010 to 2020, revenues grew at a 59.2% average annual rate, while its stock rose at 44% a year. The company finished the 2020 calendar year at about $4.5 billion in revenue, and its trailing 12 months have surged close to $5.5 billion.\nThe company now has more than 1,266 customers with a million or more dollars in recurring revenue, and is seeing this number grow at a substantial rate, including 25% in its most recent quarter.\nBeyond the numbers, the company’s technology, which enables companies to automate and implement digital workflows, continues to prove robust and best of breed. The most recent release of its Rome platform, three additional acquisitions to expand its portfolio and a deepened partnership with Microsoft are just a few recent highlights that provide the company a pathway to growth that should accelerate based on trends including app modernization, hybrid work, workflow automation, and even enterprise ESG initiatives.\nIt’s hard to see ServiceNow not providing the robust growth that will take its market cap above $200 billion. The company’s market value is about $138 billion as of Monday.\n2. Qualcomm:Qualcomm’s strong earnings report released last week — earnings per share jumped 76% year over year and revenue rose 43% — helped drive the stock to over $160 from the low $120s in mid-October.\nConsequently, that took the company’s market cap from about $145 billion to over $180 billion in just a matter of days. It serves as a timely reminder of how quickly a tech company in the right markets can produce momentum.\nQualcomm, while best known as a chip provider for mobile handsets, is rapidly becoming a much bigger force in many categories, including the internet of things (IoT), automotive and wireless RFFE. With IoT and wireless RFFE surpassing a billion dollars a quarter in revenue, and automotive reaching nearly a billion in annual revenue with a $10 billion design pipeline, the company is becoming increasingly diversified. Thirty-eight percent of revenue in its QCT semiconductor business is now unrelated to handsets.\nPerhaps these adjacent business successes alone could catapult the company’s market value to over $200 billion, but what Qualcomm also has going for it is an undisputable global market leadership in 5G, which will continue to accelerate its handset business, as well as all of its adjacencies and massive licensing business.\n3. AMD: I’ve been critical at times of Advanced Micro Devices,and sometimes you have to lean into calls you get wrong. While Intel under new CEO Pat Gelsinger shows more ambition and clear direction, AMD under Lisa Su has been on an absolute tear.\nIn August, Mercury Research reported that AMD’s 22.5% x86 market share was its best in 14 years. With 4.2% year-over-year market share growth in its second quarter and another 54% overall revenue growth in the third quarter, the company’s market share gains look likely to continue.\nWhile I do think Intel is quickly patching its gaps and going to be a much more robust competitor, I believe the overall demand for CPUs (central processing units), GPUs (graphics processing units) and FPGAs (field-programmable gate arrays) will drive a larger total addressable market, and AMD’s going to grow revenues even if market share gains level off.\nSpeaking of FPGA’s, the impending Xilinx deal, which I believe will gain regulatory approval, hasn’t been accounted for by many investors.\nAMD’s market value rose to over $180 billion Monday after the stock surged more than 10%. The company on Monday announced a range of news, including the fact that Meta will use its Epyc processors in its data center computers.\nAfter those three, I would add Micron Technology as an honorable mention. The company sits at closer to $85 billion in market cap. Still, as our thirst for compute continues to grow, the need for memory technology will scale dramatically, making Micron a significant beneficiary along with the likes of Samsung, which already sits well inside mega-cap territory.","news_type":1},"isVote":1,"tweetType":1,"viewCount":849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879254707,"gmtCreate":1636729989347,"gmtModify":1636729989449,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"It will go up again&nbsp;","listText":"It will go up again&nbsp;","text":"It will go up again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879254707","repostId":"1139324750","repostType":4,"repost":{"id":"1139324750","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636729318,"share":"https://www.laohu8.com/m/news/1139324750?lang=&edition=full","pubTime":"2021-11-12 23:01","market":"us","language":"en","title":"Nvidia shares fell nearly 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1139324750","media":"Tiger Newspress","summary":"Nvidia shares fell nearly 2% in morning trading.Wedbush analyst Matt Bryson downgraded NVIDIA Corp t","content":"<p>Nvidia&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/11eee16e740f662501f2bc3de305f18c\" tg-width=\"871\" tg-height=\"618\" width=\"100%\" height=\"auto\"><b>Wedbush</b>&nbsp;analyst Matt Bryson downgraded&nbsp;<b>NVIDIA Corp</b>&nbsp;to Neutral from&nbsp;Outperform with a price target of $300, up from $220.</p>\n<p>The analyst cites valuation for the downgrade, with the shares trading at 55 times his 2024 numbers.</p>\n<p>He would have to lift the multiple to 67x to justify Outperform, suggesting Nvidia valued at ~7X its stated 2024 TAM and ~25X sales. Conversely, he would have to double his sales growth assumptions (from ~20% to ~40%) over the next couple of years to continue to use a 40X multiple to value Nvidia.</p>\n<p>However, Bryson believes the combination of \"unprecedented demand\" for both data center and client offerings will allow Nvidia to exceed expectations again next week when its reports.</p>\n<p>Nvidia's continued work in building out its AI software will further solidify its AI leadership.</p>\n<p>Client GPUs have again become difficult to source, helped by a combination of solid gaming demand and crypto mining requirements.</p>\n<p>New opportunities, particularly the Metaverse and its graphics-intensive requirements, have started to realize the increased investment.</p>\n<p>He sees no \"negative catalyst\" for the stock and improving fundamentals for Nvidia but downgrades the shares on valuation.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia shares fell nearly 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia shares fell nearly 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-12 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nvidia&nbsp;shares&nbsp;fell&nbsp;nearly&nbsp;2%&nbsp;in&nbsp;morning&nbsp;trading.<img src=\"https://static.tigerbbs.com/11eee16e740f662501f2bc3de305f18c\" tg-width=\"871\" tg-height=\"618\" width=\"100%\" height=\"auto\"><b>Wedbush</b>&nbsp;analyst Matt Bryson downgraded&nbsp;<b>NVIDIA Corp</b>&nbsp;to Neutral from&nbsp;Outperform with a price target of $300, up from $220.</p>\n<p>The analyst cites valuation for the downgrade, with the shares trading at 55 times his 2024 numbers.</p>\n<p>He would have to lift the multiple to 67x to justify Outperform, suggesting Nvidia valued at ~7X its stated 2024 TAM and ~25X sales. Conversely, he would have to double his sales growth assumptions (from ~20% to ~40%) over the next couple of years to continue to use a 40X multiple to value Nvidia.</p>\n<p>However, Bryson believes the combination of \"unprecedented demand\" for both data center and client offerings will allow Nvidia to exceed expectations again next week when its reports.</p>\n<p>Nvidia's continued work in building out its AI software will further solidify its AI leadership.</p>\n<p>Client GPUs have again become difficult to source, helped by a combination of solid gaming demand and crypto mining requirements.</p>\n<p>New opportunities, particularly the Metaverse and its graphics-intensive requirements, have started to realize the increased investment.</p>\n<p>He sees no \"negative catalyst\" for the stock and improving fundamentals for Nvidia but downgrades the shares on valuation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139324750","content_text":"Nvidia shares fell nearly 2% in morning trading.Wedbush analyst Matt Bryson downgraded NVIDIA Corp to Neutral from Outperform with a price target of $300, up from $220.\nThe analyst cites valuation for the downgrade, with the shares trading at 55 times his 2024 numbers.\nHe would have to lift the multiple to 67x to justify Outperform, suggesting Nvidia valued at ~7X its stated 2024 TAM and ~25X sales. Conversely, he would have to double his sales growth assumptions (from ~20% to ~40%) over the next couple of years to continue to use a 40X multiple to value Nvidia.\nHowever, Bryson believes the combination of \"unprecedented demand\" for both data center and client offerings will allow Nvidia to exceed expectations again next week when its reports.\nNvidia's continued work in building out its AI software will further solidify its AI leadership.\nClient GPUs have again become difficult to source, helped by a combination of solid gaming demand and crypto mining requirements.\nNew opportunities, particularly the Metaverse and its graphics-intensive requirements, have started to realize the increased investment.\nHe sees no \"negative catalyst\" for the stock and improving fundamentals for Nvidia but downgrades the shares on valuation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855720118,"gmtCreate":1635403802747,"gmtModify":1635403802849,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Wow. Good","listText":"Wow. Good","text":"Wow. Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855720118","repostId":"2178237269","repostType":4,"repost":{"id":"2178237269","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635376679,"share":"https://www.laohu8.com/m/news/2178237269?lang=&edition=full","pubTime":"2021-10-28 07:17","market":"us","language":"en","title":"Microsoft nearly overtakes Apple as most valuable company","url":"https://stock-news.laohu8.com/highlight/detail?id=2178237269","media":"Reuters","summary":"(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuabl","content":"<p>(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuable company on Wednesday, a day before the iPhone maker reports its quarterly results.</p>\n<p>Fueled by strong quarterly growth in its Azure cloud-computing business, Microsoft's shares jumped 4.2% to end at a record $323.17, elevating the software maker's market capitalization to $2.426 trillion, just short of Apple's $2.461 trillion valuation, according to Refinitiv data.</p>\n<p>Apple's shares dipped 0.3% ahead of its report due after the bell on Thursday, with investors focused on how the global supply-chain crisis is challenging the company's ability to meet demand for its iPhones.</p>\n<p>Microsoft's stock has rallied 45% this year, with pandemic-induced demand for its cloud-based services driving sales. Shares of Apple have climbed 12% in 2021.</p>\n<p>Apple's stock market value overtook Microsoft's in 2010 as the iPhone made it the world's premier consumer technology company. The two companies have taken turns as Wall Street's most valuable company in recent years, with Apple holding the title since mid-2020.</p>\n<p>In its report late on Tuesday, Microsoft forecast a strong end to the calendar year thanks to its booming cloud business, but it warned that supply-chain woes will continue to dog key units, such as those producing its Surface laptops and Xbox gaming consoles.</p>\n<p>Analysts on average expect Apple to report September-quarter revenue up 31% to $84.8 billion and adjusted earnings per share of $1.24, according to Refinitiv.</p>\n<p>Read:<a href=\"https://laohu8.com/NW/1178636160\" target=\"_blank\">Apple Reports Earnings Thursday. Here’s What to Expect.</a></p>\n<p>Read:<a href=\"https://laohu8.com/NW/1188688981\" target=\"_blank\">Amazon Earnings Are Coming Thursday. Here’s What to Expect.</a></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft nearly overtakes Apple as most valuable company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft nearly overtakes Apple as most valuable company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-28 07:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuable company on Wednesday, a day before the iPhone maker reports its quarterly results.</p>\n<p>Fueled by strong quarterly growth in its Azure cloud-computing business, Microsoft's shares jumped 4.2% to end at a record $323.17, elevating the software maker's market capitalization to $2.426 trillion, just short of Apple's $2.461 trillion valuation, according to Refinitiv data.</p>\n<p>Apple's shares dipped 0.3% ahead of its report due after the bell on Thursday, with investors focused on how the global supply-chain crisis is challenging the company's ability to meet demand for its iPhones.</p>\n<p>Microsoft's stock has rallied 45% this year, with pandemic-induced demand for its cloud-based services driving sales. Shares of Apple have climbed 12% in 2021.</p>\n<p>Apple's stock market value overtook Microsoft's in 2010 as the iPhone made it the world's premier consumer technology company. The two companies have taken turns as Wall Street's most valuable company in recent years, with Apple holding the title since mid-2020.</p>\n<p>In its report late on Tuesday, Microsoft forecast a strong end to the calendar year thanks to its booming cloud business, but it warned that supply-chain woes will continue to dog key units, such as those producing its Surface laptops and Xbox gaming consoles.</p>\n<p>Analysts on average expect Apple to report September-quarter revenue up 31% to $84.8 billion and adjusted earnings per share of $1.24, according to Refinitiv.</p>\n<p>Read:<a href=\"https://laohu8.com/NW/1178636160\" target=\"_blank\">Apple Reports Earnings Thursday. Here’s What to Expect.</a></p>\n<p>Read:<a href=\"https://laohu8.com/NW/1188688981\" target=\"_blank\">Amazon Earnings Are Coming Thursday. Here’s What to Expect.</a></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178237269","content_text":"(Reuters) - A surge in Microsoft Corp's shares nearly unseated Apple Inc as the world's most valuable company on Wednesday, a day before the iPhone maker reports its quarterly results.\nFueled by strong quarterly growth in its Azure cloud-computing business, Microsoft's shares jumped 4.2% to end at a record $323.17, elevating the software maker's market capitalization to $2.426 trillion, just short of Apple's $2.461 trillion valuation, according to Refinitiv data.\nApple's shares dipped 0.3% ahead of its report due after the bell on Thursday, with investors focused on how the global supply-chain crisis is challenging the company's ability to meet demand for its iPhones.\nMicrosoft's stock has rallied 45% this year, with pandemic-induced demand for its cloud-based services driving sales. Shares of Apple have climbed 12% in 2021.\nApple's stock market value overtook Microsoft's in 2010 as the iPhone made it the world's premier consumer technology company. The two companies have taken turns as Wall Street's most valuable company in recent years, with Apple holding the title since mid-2020.\nIn its report late on Tuesday, Microsoft forecast a strong end to the calendar year thanks to its booming cloud business, but it warned that supply-chain woes will continue to dog key units, such as those producing its Surface laptops and Xbox gaming consoles.\nAnalysts on average expect Apple to report September-quarter revenue up 31% to $84.8 billion and adjusted earnings per share of $1.24, according to Refinitiv.\nRead:Apple Reports Earnings Thursday. Here’s What to Expect.\nRead:Amazon Earnings Are Coming Thursday. Here’s What to Expect.","news_type":1},"isVote":1,"tweetType":1,"viewCount":770,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820567156,"gmtCreate":1633404140378,"gmtModify":1633404306674,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820567156","repostId":"1121300578","repostType":4,"repost":{"id":"1121300578","pubTimestamp":1633395123,"share":"https://www.laohu8.com/m/news/1121300578?lang=&edition=full","pubTime":"2021-10-05 08:52","market":"us","language":"en","title":"SoFi Technologies stock dips after offering $1.1B of convertible notes","url":"https://stock-news.laohu8.com/highlight/detail?id=1121300578","media":"Seekingalpha","summary":"SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offeri","content":"<ul>\n <li>SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offering last week.</li>\n <li>In today's trading alone, the stock&nbsp;dips 1.8%&nbsp;in early afternoon trading.</li>\n <li>On Sept. 29, the company boosted the size of its debt offering to $1.1B from $750M. The notes can be converted into SoFi (SOFI) shares on or after April 15, 2026 until the trading day preceding Oct. 15, 2026.</li>\n <li>Shares of companies that issue convertible debt often decline as the conversion of the debt to shares would increase the number of shares outstanding, potentially diluting existing stockholders' stakes.</li>\n <li>Previously (Sept. 29),SoFi Technologies prices $1.1B of convertible notes offering</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SoFi Technologies stock dips after offering $1.1B of convertible notes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoFi Technologies stock dips after offering $1.1B of convertible notes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 08:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748268-sofi-technologies-stock-dips-after-offering-11b-of-convertible-notes><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offering last week.\nIn today's trading alone, the stock dips 1.8% in early afternoon trading.\nOn Sept. 29,...</p>\n\n<a href=\"https://seekingalpha.com/news/3748268-sofi-technologies-stock-dips-after-offering-11b-of-convertible-notes\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOFI":"SoFi Technologies Inc."},"source_url":"https://seekingalpha.com/news/3748268-sofi-technologies-stock-dips-after-offering-11b-of-convertible-notes","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121300578","content_text":"SoFi Technologies(NASDAQ:SOFI)shares fall 5.2% since the fintech announced a convertible debt offering last week.\nIn today's trading alone, the stock dips 1.8% in early afternoon trading.\nOn Sept. 29, the company boosted the size of its debt offering to $1.1B from $750M. The notes can be converted into SoFi (SOFI) shares on or after April 15, 2026 until the trading day preceding Oct. 15, 2026.\nShares of companies that issue convertible debt often decline as the conversion of the debt to shares would increase the number of shares outstanding, potentially diluting existing stockholders' stakes.\nPreviously (Sept. 29),SoFi Technologies prices $1.1B of convertible notes offering","news_type":1},"isVote":1,"tweetType":1,"viewCount":634,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":887940095,"gmtCreate":1631964571917,"gmtModify":1632805057856,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Yeah, seems like.","listText":"Yeah, seems like.","text":"Yeah, seems like.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887940095","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":12,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814327435,"gmtCreate":1630768308127,"gmtModify":1632905975890,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Wow… meme","listText":"Wow… meme","text":"Wow… meme","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814327435","repostId":"1189766406","repostType":4,"isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813942250,"gmtCreate":1630125313470,"gmtModify":1704956337419,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Rocket again","listText":"Rocket again","text":"Rocket again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/813942250","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://www.laohu8.com/m/news/1199074003?lang=&edition=full","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184432369,"gmtCreate":1623721147551,"gmtModify":1634029601126,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"This is new IPO stock?","listText":"This is new IPO stock?","text":"This is new IPO stock?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/184432369","repostId":"1180739794","repostType":4,"repost":{"id":"1180739794","pubTimestamp":1623720576,"share":"https://www.laohu8.com/m/news/1180739794?lang=&edition=full","pubTime":"2021-06-15 09:29","market":"us","language":"en","title":"This cannabis stock is a new Reddit favorite","url":"https://stock-news.laohu8.com/highlight/detail?id=1180739794","media":"CNN Business","summary":"New York (CNN Business) - Cannabis company Tilray, which recently merged with rival Aphria, has seen","content":"<p><b>New York (CNN Business)&nbsp;</b>-&nbsp;Cannabis company Tilray, which recently merged with rival Aphria, has seen its stock surge as of late thanks to — you guessed it — love from the Reddit crowd.</p>\n<p>As backers tout the growing number of states legalizing recreational and medical marijuana, some investors are holding out for the dream scenario of federal legalization — even though that might be a stretch in the near term.</p>\n<p>But are investors going a little crazy?Tilray&nbsp;(TLRY)&nbsp;is now up more than 130% this year. That's much higher than the gains for rivalsCanopy Growth&nbsp;(CGC)&nbsp;and&nbsp;Cronos&nbsp;(CRON), which have the backing of consumer products giantsConstellation Brands(STZ)andAltria(MO), respectively.</p>\n<p>Short-sellers are targeting Tilray. And Redditors have gleefully tried to squeeze the shorts — investors who borrow stocks and sell them with hopes of buying them back at a lower price.</p>\n<p>If a stock suddenly starts to rise, short-sellers have no choice but to buy it back or face prohibitively large losses. That's a big reason behind the recent spikes in&nbsp;AMC(AMC),GameStop(GME)&nbsp;and other stocks that the Reddit community has glommed onto this year.</p>\n<p>One Reddit user&nbsp;wrote in a post&nbsp;last week that Tilray \"is a movement,\" adding that the company has \"fantastic stats\" and is \"a worthy opponent to AMC\" as a meme stock.</p>\n<p>The short-sellers have seemingly taken control in this battle lately though. After a 6% pop in Tilray's stock last Wednesday, share prices have fallen for the past three trading days.</p>\n<p>But some backers aren't deterred by the recent pullback. One Redditor on the site's Tilray board&nbsp;wrote the following message&nbsp;to any would be short sellers: \"Weed Stocks to Bears: I'm not leaving.\"</p>\n<p>The post, which also mentioned cannabis stocksAurora(ACB)andSundial Growers(SNDL), showed a clip of Leonardo DiCaprio's inspirational speech to employes from \"The Wolf of Wall Street\" in which his Jordan Belfort character exclaimed he wasn't going anywhere.</p>\n<p>The Reddit community also seems to appreciate that Tilray CEO Irwin Simon is acknowledging their support. In an interview with CNBC last week, Simon said \"we love having them as part of our shareholder base\" in response to a question about the retail investor interest in the stock.</p>\n<p>One commenter referred to Simon last week as a \"diamond\" — the ultimate Reddit compliment.</p>\n<p>\"[He] wants to build a global green giant. This dude wants to take us to tendie town gentleman,\" the poster said, using the Reddit lingo \"tendie\" to describe trading profits.</p>\n<p>\"This company has a shot to literally rocket to the top as a fundamental and strong global brand,\" the Reddit user added.</p>\n<p>Still, Tilray's faithful may have a tough time convincing the Wall Street establishment that this is a stock worth owning.</p>\n<p>Analysts who cover the stock are lukewarm on its prospects. Only four have a buy rating on Tilray, compared with 13 holds and one sell. What's more, the consensus target price is about $19 — right around where the stock is currently trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This cannabis stock is a new Reddit favorite</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis cannabis stock is a new Reddit favorite\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 09:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/06/14/investing/tilray-reddit-cannabis-stocks/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business) - Cannabis company Tilray, which recently merged with rival Aphria, has seen its stock surge as of late thanks to — you guessed it — love from the Reddit crowd.\nAs backers tout...</p>\n\n<a href=\"https://edition.cnn.com/2021/06/14/investing/tilray-reddit-cannabis-stocks/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://edition.cnn.com/2021/06/14/investing/tilray-reddit-cannabis-stocks/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180739794","content_text":"New York (CNN Business) - Cannabis company Tilray, which recently merged with rival Aphria, has seen its stock surge as of late thanks to — you guessed it — love from the Reddit crowd.\nAs backers tout the growing number of states legalizing recreational and medical marijuana, some investors are holding out for the dream scenario of federal legalization — even though that might be a stretch in the near term.\nBut are investors going a little crazy?Tilray (TLRY) is now up more than 130% this year. That's much higher than the gains for rivalsCanopy Growth (CGC) and Cronos (CRON), which have the backing of consumer products giantsConstellation Brands(STZ)andAltria(MO), respectively.\nShort-sellers are targeting Tilray. And Redditors have gleefully tried to squeeze the shorts — investors who borrow stocks and sell them with hopes of buying them back at a lower price.\nIf a stock suddenly starts to rise, short-sellers have no choice but to buy it back or face prohibitively large losses. That's a big reason behind the recent spikes in AMC(AMC),GameStop(GME) and other stocks that the Reddit community has glommed onto this year.\nOne Reddit user wrote in a post last week that Tilray \"is a movement,\" adding that the company has \"fantastic stats\" and is \"a worthy opponent to AMC\" as a meme stock.\nThe short-sellers have seemingly taken control in this battle lately though. After a 6% pop in Tilray's stock last Wednesday, share prices have fallen for the past three trading days.\nBut some backers aren't deterred by the recent pullback. One Redditor on the site's Tilray board wrote the following message to any would be short sellers: \"Weed Stocks to Bears: I'm not leaving.\"\nThe post, which also mentioned cannabis stocksAurora(ACB)andSundial Growers(SNDL), showed a clip of Leonardo DiCaprio's inspirational speech to employes from \"The Wolf of Wall Street\" in which his Jordan Belfort character exclaimed he wasn't going anywhere.\nThe Reddit community also seems to appreciate that Tilray CEO Irwin Simon is acknowledging their support. In an interview with CNBC last week, Simon said \"we love having them as part of our shareholder base\" in response to a question about the retail investor interest in the stock.\nOne commenter referred to Simon last week as a \"diamond\" — the ultimate Reddit compliment.\n\"[He] wants to build a global green giant. This dude wants to take us to tendie town gentleman,\" the poster said, using the Reddit lingo \"tendie\" to describe trading profits.\n\"This company has a shot to literally rocket to the top as a fundamental and strong global brand,\" the Reddit user added.\nStill, Tilray's faithful may have a tough time convincing the Wall Street establishment that this is a stock worth owning.\nAnalysts who cover the stock are lukewarm on its prospects. Only four have a buy rating on Tilray, compared with 13 holds and one sell. What's more, the consensus target price is about $19 — right around where the stock is currently trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":65,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194447080,"gmtCreate":1621396637740,"gmtModify":1634189481282,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Good and bravo...","listText":"Good and bravo...","text":"Good and bravo...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/194447080","repostId":"2136738931","repostType":4,"repost":{"id":"2136738931","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1621318800,"share":"https://www.laohu8.com/m/news/2136738931?lang=&edition=full","pubTime":"2021-05-18 14:20","market":"hk","language":"en","title":"JD Logistics launches Hong Kong IPO to raise up to US$3.4 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2136738931","media":"Tiger Newspress","summary":"The logistics arm of Chinese e-commerce giant JD.com started marketing its Hong Kong initial public offering  to retail investors on Monday at a price range of HK$39.36 to HK$43.36 per share, which could see the firm raise as much as HK$26.4 billion  if the deal is priced at the top end.JD Logistics' public offering will run from Monday to Friday. Its shares are expected to begin trading on the Hong Kong bourse's main board on May 28.JD Logistics' offering is expected to be the second multibilli","content":"<p>The logistics arm of Chinese e-commerce giant JD.com started marketing its Hong Kong initial public offering (IPO) to retail investors on Monday at a price range of HK$39.36 to HK$43.36 per share, which could see the firm raise as much as HK$26.4 billion (US$3.4 billion) if the deal is priced at the top end.<a href=\"https://www.itiger.com/mi/ipo?feature=Push\" target=\"_blank\"><b>（Click here To apply for the JD Logistics Shares）</b></a><b></b></p><p>JD Logistics' public offering will run from Monday to Friday. Its shares are expected to begin trading on the Hong Kong bourse's main board on May 28.</p><p>JD Logistics plans to sell 609.2 million shares, representing 10 per cent of its enlarged share capital. There is an over-allotment option to sell up to 91.4 million more shares if there is a strong demand.</p><p><img src=\"https://static.tigerbbs.com/cd9320033ea7302952fa2cb6ece8339a\" tg-width=\"958\" tg-height=\"464\"></p><p>Your application must be for a minimum of 100 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.</p><p><img src=\"https://static.tigerbbs.com/b1f72efeb4b54a02dbfe728ebb1099dd\" tg-width=\"958\" tg-height=\"437\"></p><p>JD Logistics' offering is expected to be the second multibillion-dollar IPO on the Hong Kong bourse this year, after Tencent-backed short video platform Kuaishou Technology raised US$6.2 billion in January. The Kuaishou offering was the biggest IPO globally so far this year.</p><p>Eight cornerstone investors have committed to buy a total of US$1.5 billion worth of JD Logistics shares, which would account for about 39 per cent of its global offering if the deal is priced at the top end.</p><p>The investors include Softbank, Singapore sovereign wealth fund Temasek Holdings, China Structural Reform Fund and asset managers such as Blackstone, Tiger Global Management and others.</p><p>BofA Securities, Goldman Sachs and Haitong International are acting as joint sponsors on the transaction, while UBS is serving as a financial adviser.</p><p>Assuming the deal is priced at the top end, JD Logistics' market capitalisation would be HK$264.1 billion, valuing it higher than ZTO Express.</p><p>Shanghai-based ZTO, which counts Alibaba Group Holding as one of its shareholders, had a market capitalisation of HK$180.7 billion when it listed in Hong Kong through a secondary listing last September. Alibaba owns the South China Morning Post.</p><p>Investors will be keen to learn more about JD Logistics' plan to churn out a profit. The Beijing-based firm said in its prospectus that it expects a bigger net loss for this year, after racking up losses of 2.8 billion yuan (US$435 million) in 2018, 2.2 billion yuan in 2019 and 4 billion yuan in 2020.</p><p>\"As we currently prioritise growth of our business and expansion of our market share over profitability, there can be significant fluctuations in our profitability profile in the near-to-medium term,\" the company said in its draft prospectus.</p><p>JD Logistics is seeking to differentiate itself from other players, such as ZTO and Yunda Holding, by touting itself as a technology-driven logistic services provider using autonomous mobile robots, sorting robots and self-driving vehicles to enhance delivery speed and accuracy.</p><p>Pitching the stock sale with a tech angle could help JD Logistics paint a more positive outlook. This is because competition is particularly keen in the express delivery sector, with reports of some newer players offering services at below cost to grab business.</p><p>Over the past three years, the average revenue per parcel for express delivery companies declined by 50 per cent to 60 per cent owing to intensive market competition, according to Charlie Chen, an analyst at China Renaissance.</p><p>SF Express, China's top delivery service provider, shocked the market this month after it forecast a first-quarter loss of 1.1 billion yuan, triggering a sell-off of its stock. As of Friday's close, its share price in Shanghai was almost halved from its mid-February peak.</p><p>Five players - ZTO, YTO Express, STO Express, SF Express and Yunda Holding - account for nearly 80 per cent of China's express delivery service market.</p><p>China is the biggest logistics market in the world in terms of spending, with total logistics spending reaching 14.9 trillion yuan in 2020. That is expected to increase to 19.3 trillion yuan by 2025, according to data from research firm China Insights Consultancy cited in JD Logistics' prospectus.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Logistics launches Hong Kong IPO to raise up to US$3.4 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Logistics launches Hong Kong IPO to raise up to US$3.4 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-18 14:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The logistics arm of Chinese e-commerce giant JD.com started marketing its Hong Kong initial public offering (IPO) to retail investors on Monday at a price range of HK$39.36 to HK$43.36 per share, which could see the firm raise as much as HK$26.4 billion (US$3.4 billion) if the deal is priced at the top end.<a href=\"https://www.itiger.com/mi/ipo?feature=Push\" target=\"_blank\"><b>（Click here To apply for the JD Logistics Shares）</b></a><b></b></p><p>JD Logistics' public offering will run from Monday to Friday. Its shares are expected to begin trading on the Hong Kong bourse's main board on May 28.</p><p>JD Logistics plans to sell 609.2 million shares, representing 10 per cent of its enlarged share capital. There is an over-allotment option to sell up to 91.4 million more shares if there is a strong demand.</p><p><img src=\"https://static.tigerbbs.com/cd9320033ea7302952fa2cb6ece8339a\" tg-width=\"958\" tg-height=\"464\"></p><p>Your application must be for a minimum of 100 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.</p><p><img src=\"https://static.tigerbbs.com/b1f72efeb4b54a02dbfe728ebb1099dd\" tg-width=\"958\" tg-height=\"437\"></p><p>JD Logistics' offering is expected to be the second multibillion-dollar IPO on the Hong Kong bourse this year, after Tencent-backed short video platform Kuaishou Technology raised US$6.2 billion in January. The Kuaishou offering was the biggest IPO globally so far this year.</p><p>Eight cornerstone investors have committed to buy a total of US$1.5 billion worth of JD Logistics shares, which would account for about 39 per cent of its global offering if the deal is priced at the top end.</p><p>The investors include Softbank, Singapore sovereign wealth fund Temasek Holdings, China Structural Reform Fund and asset managers such as Blackstone, Tiger Global Management and others.</p><p>BofA Securities, Goldman Sachs and Haitong International are acting as joint sponsors on the transaction, while UBS is serving as a financial adviser.</p><p>Assuming the deal is priced at the top end, JD Logistics' market capitalisation would be HK$264.1 billion, valuing it higher than ZTO Express.</p><p>Shanghai-based ZTO, which counts Alibaba Group Holding as one of its shareholders, had a market capitalisation of HK$180.7 billion when it listed in Hong Kong through a secondary listing last September. Alibaba owns the South China Morning Post.</p><p>Investors will be keen to learn more about JD Logistics' plan to churn out a profit. The Beijing-based firm said in its prospectus that it expects a bigger net loss for this year, after racking up losses of 2.8 billion yuan (US$435 million) in 2018, 2.2 billion yuan in 2019 and 4 billion yuan in 2020.</p><p>\"As we currently prioritise growth of our business and expansion of our market share over profitability, there can be significant fluctuations in our profitability profile in the near-to-medium term,\" the company said in its draft prospectus.</p><p>JD Logistics is seeking to differentiate itself from other players, such as ZTO and Yunda Holding, by touting itself as a technology-driven logistic services provider using autonomous mobile robots, sorting robots and self-driving vehicles to enhance delivery speed and accuracy.</p><p>Pitching the stock sale with a tech angle could help JD Logistics paint a more positive outlook. This is because competition is particularly keen in the express delivery sector, with reports of some newer players offering services at below cost to grab business.</p><p>Over the past three years, the average revenue per parcel for express delivery companies declined by 50 per cent to 60 per cent owing to intensive market competition, according to Charlie Chen, an analyst at China Renaissance.</p><p>SF Express, China's top delivery service provider, shocked the market this month after it forecast a first-quarter loss of 1.1 billion yuan, triggering a sell-off of its stock. As of Friday's close, its share price in Shanghai was almost halved from its mid-February peak.</p><p>Five players - ZTO, YTO Express, STO Express, SF Express and Yunda Holding - account for nearly 80 per cent of China's express delivery service market.</p><p>China is the biggest logistics market in the world in terms of spending, with total logistics spending reaching 14.9 trillion yuan in 2020. That is expected to increase to 19.3 trillion yuan by 2025, according to data from research firm China Insights Consultancy cited in JD Logistics' prospectus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02618":"京东物流"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136738931","content_text":"The logistics arm of Chinese e-commerce giant JD.com started marketing its Hong Kong initial public offering (IPO) to retail investors on Monday at a price range of HK$39.36 to HK$43.36 per share, which could see the firm raise as much as HK$26.4 billion (US$3.4 billion) if the deal is priced at the top end.（Click here To apply for the JD Logistics Shares）JD Logistics' public offering will run from Monday to Friday. Its shares are expected to begin trading on the Hong Kong bourse's main board on May 28.JD Logistics plans to sell 609.2 million shares, representing 10 per cent of its enlarged share capital. There is an over-allotment option to sell up to 91.4 million more shares if there is a strong demand.Your application must be for a minimum of 100 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.JD Logistics' offering is expected to be the second multibillion-dollar IPO on the Hong Kong bourse this year, after Tencent-backed short video platform Kuaishou Technology raised US$6.2 billion in January. The Kuaishou offering was the biggest IPO globally so far this year.Eight cornerstone investors have committed to buy a total of US$1.5 billion worth of JD Logistics shares, which would account for about 39 per cent of its global offering if the deal is priced at the top end.The investors include Softbank, Singapore sovereign wealth fund Temasek Holdings, China Structural Reform Fund and asset managers such as Blackstone, Tiger Global Management and others.BofA Securities, Goldman Sachs and Haitong International are acting as joint sponsors on the transaction, while UBS is serving as a financial adviser.Assuming the deal is priced at the top end, JD Logistics' market capitalisation would be HK$264.1 billion, valuing it higher than ZTO Express.Shanghai-based ZTO, which counts Alibaba Group Holding as one of its shareholders, had a market capitalisation of HK$180.7 billion when it listed in Hong Kong through a secondary listing last September. Alibaba owns the South China Morning Post.Investors will be keen to learn more about JD Logistics' plan to churn out a profit. The Beijing-based firm said in its prospectus that it expects a bigger net loss for this year, after racking up losses of 2.8 billion yuan (US$435 million) in 2018, 2.2 billion yuan in 2019 and 4 billion yuan in 2020.\"As we currently prioritise growth of our business and expansion of our market share over profitability, there can be significant fluctuations in our profitability profile in the near-to-medium term,\" the company said in its draft prospectus.JD Logistics is seeking to differentiate itself from other players, such as ZTO and Yunda Holding, by touting itself as a technology-driven logistic services provider using autonomous mobile robots, sorting robots and self-driving vehicles to enhance delivery speed and accuracy.Pitching the stock sale with a tech angle could help JD Logistics paint a more positive outlook. This is because competition is particularly keen in the express delivery sector, with reports of some newer players offering services at below cost to grab business.Over the past three years, the average revenue per parcel for express delivery companies declined by 50 per cent to 60 per cent owing to intensive market competition, according to Charlie Chen, an analyst at China Renaissance.SF Express, China's top delivery service provider, shocked the market this month after it forecast a first-quarter loss of 1.1 billion yuan, triggering a sell-off of its stock. As of Friday's close, its share price in Shanghai was almost halved from its mid-February peak.Five players - ZTO, YTO Express, STO Express, SF Express and Yunda Holding - account for nearly 80 per cent of China's express delivery service market.China is the biggest logistics market in the world in terms of spending, with total logistics spending reaching 14.9 trillion yuan in 2020. That is expected to increase to 19.3 trillion yuan by 2025, according to data from research firm China Insights Consultancy cited in JD Logistics' prospectus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":879799564,"gmtCreate":1636770294362,"gmtModify":1636770294468,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879799564","repostId":"1116750872","repostType":4,"repost":{"id":"1116750872","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1636761765,"share":"https://www.laohu8.com/m/news/1116750872?lang=&edition=full","pubTime":"2021-11-13 08:02","market":"us","language":"en","title":"Meta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?","url":"https://stock-news.laohu8.com/highlight/detail?id=1116750872","media":"Benzinga","summary":"Meta Platforms Inc is having a strong close thus far to end the week, up almost 3.5% and only $7 off","content":"<p><b>Meta Platforms Inc</b>&nbsp;is having a strong close thus far to end the week, up almost 3.5% and only $7 off the weekly highs.</p>\n<p><b>What Happened:</b>&nbsp;While the volume of shares traded is solid at 17 million vs. the 10 day average of 21 million, options traders are quite active on the day, trading more than&nbsp;672,970 options with 476,002&nbsp;being calls and 196,968&nbsp;being puts. This comes out to about 7 out of every 10 options being calls (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/c08237f8d7c163047e56072f027073d5\" tg-width=\"1001\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>What It Matters:</b>Prior to this Friday, there were 1,519,000 calls and 1,207,750 puts for a total of 2,726,000&nbsp;options. Hence this Friday's options activity and flows of 672,970 comprise 25% of the total option flows out there.</p>\n<p>Any time a stock trades 25% of its total options in one day, it means options traders are particularly active in the stock.</p>\n<p>Of note, only 11% of the options were set to expire this Friday (~300,000 options) so today's 672,970&nbsp;options suggest a lot more forward-looking flows.</p>\n<p><b>What's Next:</b>Looking at the option flows expiring next week on Nov. 19, you can see on the call side the majority of volume and open interest is between the $330 and $360 strikes. And on the put side, there is a consistent but small volume between the $340 and $300 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/e74f74fdf39ce74de7e0d6a88eb349c8\" tg-width=\"1743\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>\n<p>This suggests bullish traders are targeting&nbsp;between $330 and $360, but don't have&nbsp;much appetite above that. Meanwhile, bearish options traders don't see much downside below $300.</p>\n<p>It should be noted the steady volume of puts from $340 to $300 appears to be a mix of bullish traders selling cash-secured puts down to the $322.5 strike, but likely long stock traders seeking protection below that as the premium is very low.</p>\n<p>Hence bullish traders will want to see the $360 strike cleared by next week to lift their expectations higher while bears will want to see a weekly close below $300 to open up the downside.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Closes The Week Strong: Are Option Traders Targeting All-Time Highs?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-13 08:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Meta Platforms Inc</b>&nbsp;is having a strong close thus far to end the week, up almost 3.5% and only $7 off the weekly highs.</p>\n<p><b>What Happened:</b>&nbsp;While the volume of shares traded is solid at 17 million vs. the 10 day average of 21 million, options traders are quite active on the day, trading more than&nbsp;672,970 options with 476,002&nbsp;being calls and 196,968&nbsp;being puts. This comes out to about 7 out of every 10 options being calls (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/c08237f8d7c163047e56072f027073d5\" tg-width=\"1001\" tg-height=\"277\" width=\"100%\" height=\"auto\"></p>\n<p><b>What It Matters:</b>Prior to this Friday, there were 1,519,000 calls and 1,207,750 puts for a total of 2,726,000&nbsp;options. Hence this Friday's options activity and flows of 672,970 comprise 25% of the total option flows out there.</p>\n<p>Any time a stock trades 25% of its total options in one day, it means options traders are particularly active in the stock.</p>\n<p>Of note, only 11% of the options were set to expire this Friday (~300,000 options) so today's 672,970&nbsp;options suggest a lot more forward-looking flows.</p>\n<p><b>What's Next:</b>Looking at the option flows expiring next week on Nov. 19, you can see on the call side the majority of volume and open interest is between the $330 and $360 strikes. And on the put side, there is a consistent but small volume between the $340 and $300 strikes (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/e74f74fdf39ce74de7e0d6a88eb349c8\" tg-width=\"1743\" tg-height=\"650\" width=\"100%\" height=\"auto\"></p>\n<p>This suggests bullish traders are targeting&nbsp;between $330 and $360, but don't have&nbsp;much appetite above that. Meanwhile, bearish options traders don't see much downside below $300.</p>\n<p>It should be noted the steady volume of puts from $340 to $300 appears to be a mix of bullish traders selling cash-secured puts down to the $322.5 strike, but likely long stock traders seeking protection below that as the premium is very low.</p>\n<p>Hence bullish traders will want to see the $360 strike cleared by next week to lift their expectations higher while bears will want to see a weekly close below $300 to open up the downside.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116750872","content_text":"Meta Platforms Inc is having a strong close thus far to end the week, up almost 3.5% and only $7 off the weekly highs.\nWhat Happened: While the volume of shares traded is solid at 17 million vs. the 10 day average of 21 million, options traders are quite active on the day, trading more than 672,970 options with 476,002 being calls and 196,968 being puts. This comes out to about 7 out of every 10 options being calls (image below).\n\nWhat It Matters:Prior to this Friday, there were 1,519,000 calls and 1,207,750 puts for a total of 2,726,000 options. Hence this Friday's options activity and flows of 672,970 comprise 25% of the total option flows out there.\nAny time a stock trades 25% of its total options in one day, it means options traders are particularly active in the stock.\nOf note, only 11% of the options were set to expire this Friday (~300,000 options) so today's 672,970 options suggest a lot more forward-looking flows.\nWhat's Next:Looking at the option flows expiring next week on Nov. 19, you can see on the call side the majority of volume and open interest is between the $330 and $360 strikes. And on the put side, there is a consistent but small volume between the $340 and $300 strikes (image below).\n\nThis suggests bullish traders are targeting between $330 and $360, but don't have much appetite above that. Meanwhile, bearish options traders don't see much downside below $300.\nIt should be noted the steady volume of puts from $340 to $300 appears to be a mix of bullish traders selling cash-secured puts down to the $322.5 strike, but likely long stock traders seeking protection below that as the premium is very low.\nHence bullish traders will want to see the $360 strike cleared by next week to lift their expectations higher while bears will want to see a weekly close below $300 to open up the downside.","news_type":1},"isVote":1,"tweetType":1,"viewCount":847,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861352238,"gmtCreate":1632462135924,"gmtModify":1632464336077,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"How long it will take?","listText":"How long it will take?","text":"How long it will take?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/861352238","repostId":"1199759162","repostType":4,"repost":{"id":"1199759162","pubTimestamp":1632454663,"share":"https://www.laohu8.com/m/news/1199759162?lang=&edition=full","pubTime":"2021-09-24 11:37","market":"us","language":"en","title":"If Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop","url":"https://stock-news.laohu8.com/highlight/detail?id=1199759162","media":"investorplace","summary":"Everyone loves to throw out long-term price targets on Bitcoin.\nARK Invest fund manager Cathie Wood ","content":"<p>Everyone loves to throw out long-term price targets on&nbsp;<b><u>Bitcoin</u></b>.</p>\n<p>ARK Invest fund manager&nbsp;<b>Cathie Wood</b>&nbsp;last week reiterated her firm’s call for Bitcoin to trend toward $500,000 per coin over the next several years.&nbsp;<b>Tyler Winklevoss</b>&nbsp;of Facebook fame and big crypto enthusiast has also pounded on the table about a $500,000 long-term price target for Bitcoin.</p>\n<p>Meanwhile, the relatively conservative analyst team over at&nbsp;<b>JPMorgan</b>&nbsp;has set a theoretical long-term price target for BTC of $130,000. A leaked&nbsp;<b>Citibank</b>&nbsp;report shows that the analysts over there think that the price could climb toward $300,000. Billionaire&nbsp;<b>Tim Draper</b>&nbsp;has gone on record multiple times saying Bitcoin prices will eclipse $250,000 by the end of 2022.</p>\n<p>And, in the most bullish call of them all,&nbsp;<b>Anthony Pompliano</b>– co-founder and partner at Morgan Creek Digital Assets – has said Bitcoin prices could soar to $1 million per token in the long run.</p>\n<p>Big numbers. Yes. But can Bitcoin really soar toward $200,000? $300,000? Even $500,000 or higher in the long run?</p>\n<p>Our short answer:<b><i>Yes.</i></b></p>\n<p>And the reasoning is pretty simple. Bitcoin is the digital version of gold. The gold market is an $11 trillion market. If Bitcoin gets that big, you’re talking an $11 trillion market on 21 million tokens, which implies a price per token of about $500,000.</p>\n<p>That’s the back-of-the-envelope reasoning and math behind the $500,000 price target.</p>\n<p>Of course, that model rests on some major assumptions. One, Bitcoin is the digital version of gold, and two, the Bitcoin market will be as big as the gold market.</p>\n<p><u>We think both are fair assumptions</u>.</p>\n<p>The modern value of gold derives from&nbsp;<b><i>scarcity</i></b>. Sure, maybe once upon a time, gold was used to barter for goods or used to make swords and shields. Not too long ago, it was used in some semiconductor chips.</p>\n<p>But those days are gone. Today, gold is used for nothing. Its value is in the fact that it has finite supply and, therefore, is a good store of value.</p>\n<p>The same is true for Bitcoin. In fact, it’s even more true for Bitcoin. There are, by definition, only 21 million Bitcoins in the world. There will never be more than that. Meanwhile, in the gold market, more gold mining efforts can always be put online to increase supply as demand increases.</p>\n<p>In other words, Bitcoin has more scarcity than gold and, therefore, isn’t just the digital version of gold – it is a digital and superior version of gold.</p>\n<p>Meanwhile, Bitcoin is&nbsp;<b><i>digital</i></b>, while gold is&nbsp;<b><i>physical</i></b>, and the whole world is pivoting toward digitization these days. Media is digital. Shopping is digital. Entertainment is digital. Communications are digital. Work is digital. Health is digital. Everything is digital.</p>\n<p>In that world, money will inevitably become digital, too. Indeed, that’s already happening. Venmo. Cash App. PayPal. SoFi. All of these digital money apps are soaring in usage right now, while the volume of cash transactions is plummeting.</p>\n<p>Therefore, Bitcoin is gold made for the modern world. You can’t send gold through a social media platform, or a streaming service, or use it buy a good online.&nbsp;<b>But you can use Bitcoin for that.</b></p>\n<p>To that extent, it’s easy to see why folks will ditch their physical store of value (gold) for a digital store of value (Bitcoin) – and why the Bitcoin market will become as big as (if not bigger than) the gold market.</p>\n<p>All in all, we think the fundamental reasoning underlying the Bitcoin market supports that Bitcoin prices will trend towards $500,000 in the long run.</p>\n<p>How long will it take to get there? No one really knows. Our best guess is about 10 years – and if so, you’re talking about an asset that will increase 10X in value in 10 years.</p>\n<p><u>That’s an</u>&nbsp;<u><b><i>amazing</i></b></u>&nbsp;<u>return</u>.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf Bitcoin Really Is Digital Gold, Then $500,000 Is the Next Stop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 11:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/09/if-bitcoin-really-is-digital-gold-then-500000-is-the-next-stop/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Everyone loves to throw out long-term price targets on Bitcoin.\nARK Invest fund manager Cathie Wood last week reiterated her firm’s call for Bitcoin to trend toward $500,000 per coin over the next ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/09/if-bitcoin-really-is-digital-gold-then-500000-is-the-next-stop/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/09/if-bitcoin-really-is-digital-gold-then-500000-is-the-next-stop/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199759162","content_text":"Everyone loves to throw out long-term price targets on Bitcoin.\nARK Invest fund manager Cathie Wood last week reiterated her firm’s call for Bitcoin to trend toward $500,000 per coin over the next several years. Tyler Winklevoss of Facebook fame and big crypto enthusiast has also pounded on the table about a $500,000 long-term price target for Bitcoin.\nMeanwhile, the relatively conservative analyst team over at JPMorgan has set a theoretical long-term price target for BTC of $130,000. A leaked Citibank report shows that the analysts over there think that the price could climb toward $300,000. Billionaire Tim Draper has gone on record multiple times saying Bitcoin prices will eclipse $250,000 by the end of 2022.\nAnd, in the most bullish call of them all, Anthony Pompliano– co-founder and partner at Morgan Creek Digital Assets – has said Bitcoin prices could soar to $1 million per token in the long run.\nBig numbers. Yes. But can Bitcoin really soar toward $200,000? $300,000? Even $500,000 or higher in the long run?\nOur short answer:Yes.\nAnd the reasoning is pretty simple. Bitcoin is the digital version of gold. The gold market is an $11 trillion market. If Bitcoin gets that big, you’re talking an $11 trillion market on 21 million tokens, which implies a price per token of about $500,000.\nThat’s the back-of-the-envelope reasoning and math behind the $500,000 price target.\nOf course, that model rests on some major assumptions. One, Bitcoin is the digital version of gold, and two, the Bitcoin market will be as big as the gold market.\nWe think both are fair assumptions.\nThe modern value of gold derives from scarcity. Sure, maybe once upon a time, gold was used to barter for goods or used to make swords and shields. Not too long ago, it was used in some semiconductor chips.\nBut those days are gone. Today, gold is used for nothing. Its value is in the fact that it has finite supply and, therefore, is a good store of value.\nThe same is true for Bitcoin. In fact, it’s even more true for Bitcoin. There are, by definition, only 21 million Bitcoins in the world. There will never be more than that. Meanwhile, in the gold market, more gold mining efforts can always be put online to increase supply as demand increases.\nIn other words, Bitcoin has more scarcity than gold and, therefore, isn’t just the digital version of gold – it is a digital and superior version of gold.\nMeanwhile, Bitcoin is digital, while gold is physical, and the whole world is pivoting toward digitization these days. Media is digital. Shopping is digital. Entertainment is digital. Communications are digital. Work is digital. Health is digital. Everything is digital.\nIn that world, money will inevitably become digital, too. Indeed, that’s already happening. Venmo. Cash App. PayPal. SoFi. All of these digital money apps are soaring in usage right now, while the volume of cash transactions is plummeting.\nTherefore, Bitcoin is gold made for the modern world. You can’t send gold through a social media platform, or a streaming service, or use it buy a good online. But you can use Bitcoin for that.\nTo that extent, it’s easy to see why folks will ditch their physical store of value (gold) for a digital store of value (Bitcoin) – and why the Bitcoin market will become as big as (if not bigger than) the gold market.\nAll in all, we think the fundamental reasoning underlying the Bitcoin market supports that Bitcoin prices will trend towards $500,000 in the long run.\nHow long will it take to get there? No one really knows. Our best guess is about 10 years – and if so, you’re talking about an asset that will increase 10X in value in 10 years.\nThat’s an amazing return.","news_type":1},"isVote":1,"tweetType":1,"viewCount":674,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":162993836,"gmtCreate":1624030113525,"gmtModify":1634023823402,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Yeah&nbsp;","listText":"Yeah&nbsp;","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/162993836","repostId":"1138062216","repostType":4,"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116862140,"gmtCreate":1622789470380,"gmtModify":1634097980715,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Why BB stock soar so much this week?","listText":"Why BB stock soar so much this week?","text":"Why BB stock soar so much this week?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/116862140","repostId":"1188106021","repostType":4,"repost":{"id":"1188106021","pubTimestamp":1622777592,"share":"https://www.laohu8.com/m/news/1188106021?lang=&edition=full","pubTime":"2021-06-04 11:33","market":"us","language":"en","title":"5 Growth Stocks To Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1188106021","media":"Nasdaq","summary":"Check Out These 5 Top Growth Stocks In The Stock Market TodayInvesting in growth stocks can be a gre","content":"<p>Check Out These 5 Top Growth Stocks In The Stock Market Today</p><p>Investing in growth stocks can be a great way to make money in thestock market. For many individuals, the key objective is to construct a portfolio to at least beat inflation. But I guess it’s safe to say that most would like to beat the index, generating superior returns compared to the market’s benchmark. That way, you know you are investing right.</p><p>If you are looking for&nbsp;top growth stocks to buy, you should look for companies that could expand their top-line quickly. In general, a strong revenue growth trend may indicate that a company has excellent products that consumers can’t live without. But it’s also equally important to assess whether these companies can keep growing quickly. After all, being able to grow quickly today means nothing if it’s not sustainable over the longer term. With all that being said, let’s look at some of the best growth stocks to watch in thestock market today.</p><p>Best Growth Stocks To Watch Right Now</p><ol><li><b><a href=\"https://laohu8.com/S/BBRY\">BlackBerry</a> Ltd.</b>(NYSE: BB)</li><li><b>Cloudflare Inc.</b>(NYSE: NET)</li><li><b><a href=\"https://laohu8.com/S/SQ\">Square</a> Inc.</b>(NYSE: SQ)</li><li><b><a href=\"https://laohu8.com/S/ZNGA\">Zynga</a> Inc.</b>(NASDAQ: ZNGA)</li><li><b><a href=\"https://laohu8.com/S/TDOC\">Teladoc Health Inc.</a></b>(NYSE: TDOC)</li></ol><p><a href=\"https://laohu8.com/S/BB\">BlackBerry</a></p><p>While a big part of the rally has to do with Redditers pushing up the stock, the company’s development is what attracts me to BB stock. The company has a string of partnerships that would propel BB stock higher in the long run. Recall that the company partnered with <a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a> (NASDAQ: AMZN) to develop an app store for connected cars. If you believe that its auto app store, IVY, will be a big hit, any weakness in BB stock is an opportunity to scoop up the shares at a discount. Given all these points, would you consider BB stock a long-term investment?</p><p>Cloudflare</p><p>Cloudflare is possibly <a href=\"https://laohu8.com/S/AONE\">one</a> of the most exciting cloud companies to look out for if you are investing for the long term. For those unfamiliar with the business, Cloudflare’s aim is to build a better and safer internet. Some of the company’s potential growth drivers include serverless computing, internet of things (IoT), and 5G. These present massive opportunities for the company to tap into. With more businesses moving their operations to the cloud, Cloudflare could see explosive growth in this burgeoning cybersecurity industry. That’s because of its role in safeguarding and speeding up the internet.</p><p>From the company’s first-quarter earnings, revenue came in 51% higher year-over-year to $138.1 million. The network security and content delivery network (CDN) provider also sees strong large customer growth, with a record addition of roughly 120 large customers in the quarter. More importantly, large customers now represent greater than 50% of revenue. Following these earnings, NET stock has surged more than 20% over the past month. With such strong fundamentals, should investors buy NET stock right now?</p><p>Square</p><p>Square is another growth stock to watch capitalizing on the fintech megatrend. It combines software with hardware to enable sellers to utilize mobile devices and computing devices for payments and point-of-sale solutions. It has played a vital role in the digital economy and has empowered millions to shift to its digital payment solutions.</p><p>If you have been keeping up with the lateststock market news, you have likely heard of meme stocks. And when it comes tomeme stocks, <a href=\"https://laohu8.com/S/AMC\">AMC Entertainment</a> (NYSE: AMC) will most probably be the first to pop up in your mind. But in our article today, we are more interested in BlackBerry as it is at the forefront of two of the biggest trends today, namely IT security and autonomous driving. The meme stocks rally is sending BB stock at least 70% higher over the past week.</p><p>From its first-quarter fiscal earnings, gross profit came in 79% higher year-over-year to $964 million. In detail, Square’s Seller ecosystem generated $468 million in gross profit for the quarter, a 32% increase compared to a year earlier. Also, its Cash App generated a whopping $495 million in gross profit, an increase of 171% year-over-year. <a href=\"https://laohu8.com/S/TSS\">Total</a> net revenue for the quarter was $5.06 billion, up by 266% year-over-year. If anything, the company has also shown commendable resilience. Despite strict lockdowns around the world, its Seller’s gross profit continued to grow. All things considered, will you add SQ stock to your portfolio?</p><p>Zynga</p><p>After Gamestop (NYSE: GME), Zynga is probably the most discussed gaming company among millennials. Zynga is a company behind many successful mobile games, such as<i>Words with Friends</i>and<i>Zynga Poker,</i>just to name a few. Recently, Zynga announced the acquisition of game developer Rollic, which has launched the popular games<i>High Heels!</i>And<i>Blob Runner <a href=\"https://laohu8.com/S/DDD\">3D</a>.</i>In addition, the company has also bought the Echtra game company, which is likely to strengthen Zynga’s development capabilities for future cross-platform projects.</p><p>From its first-quarter earnings, revenue came in 68% higher year-over-year to $680 million. Following strong top-line growth, Zynga went on to raise its full-year 2021 guidance for revenue to $2.7 billion, representing a growth of 37% year-over-year. Considering the strong growth in its revenue, would you say that ZNGA stock is a top growth stock to buy and hold for the long run?</p><p>Teladoc Health</p><p>The last growth stock to watch on this list is Teladoc Health. No doubt, Teladoc did indeed benefit immensely from the pandemic. This came as no surprise seeing that the company’s plethora of telehealth services remain a vital service during the pandemic. Considering it has shed around 50% of its value since peaking in February, many investors are seeing this as an opportunity to buy TDOC stock at great discounts. Teladoc Health reported its first-quarter financials on April 28. In it, it raised full-year guidance as first-quarter revenue came in 151% higher year-over-year to a record $453.7 million.</p><p>One reason why investors are bullish is that Teladoc is slowly creating cheaper remote alternatives to the inconvenient, inefficient health care system we have today. Also, consulting firm McKinsey &amp; Company projects that the U.S. virtual care market could approach $250 billion annually after the pandemic is over. The fact that more players are getting into telemedicine is a validation of the market potential here. Teladoc’s strategic maneuvers in the past years have cemented its position as a leader in its space. Therefore, it seems to me that TDOC stock has a potentially long growth runway ahead.</p>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Growth Stocks To Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Growth Stocks To Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.nasdaq.com/articles/5-growth-stocks-to-watch-this-week-2021-06-03><strong>Nasdaq</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Check Out These 5 Top Growth Stocks In The Stock Market TodayInvesting in growth stocks can be a great way to make money in thestock market. For many individuals, the key objective is to construct a ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/5-growth-stocks-to-watch-this-week-2021-06-03\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","BB":"黑莓","SQ":"Block","NET":"Cloudflare, Inc.","ZNGA":"Zynga"},"source_url":"https://www.nasdaq.com/articles/5-growth-stocks-to-watch-this-week-2021-06-03","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188106021","content_text":"Check Out These 5 Top Growth Stocks In The Stock Market TodayInvesting in growth stocks can be a great way to make money in thestock market. For many individuals, the key objective is to construct a portfolio to at least beat inflation. But I guess it’s safe to say that most would like to beat the index, generating superior returns compared to the market’s benchmark. That way, you know you are investing right.If you are looking for top growth stocks to buy, you should look for companies that could expand their top-line quickly. In general, a strong revenue growth trend may indicate that a company has excellent products that consumers can’t live without. But it’s also equally important to assess whether these companies can keep growing quickly. After all, being able to grow quickly today means nothing if it’s not sustainable over the longer term. With all that being said, let’s look at some of the best growth stocks to watch in thestock market today.Best Growth Stocks To Watch Right NowBlackBerry Ltd.(NYSE: BB)Cloudflare Inc.(NYSE: NET)Square Inc.(NYSE: SQ)Zynga Inc.(NASDAQ: ZNGA)Teladoc Health Inc.(NYSE: TDOC)BlackBerryWhile a big part of the rally has to do with Redditers pushing up the stock, the company’s development is what attracts me to BB stock. The company has a string of partnerships that would propel BB stock higher in the long run. Recall that the company partnered with Amazon.com (NASDAQ: AMZN) to develop an app store for connected cars. If you believe that its auto app store, IVY, will be a big hit, any weakness in BB stock is an opportunity to scoop up the shares at a discount. Given all these points, would you consider BB stock a long-term investment?CloudflareCloudflare is possibly one of the most exciting cloud companies to look out for if you are investing for the long term. For those unfamiliar with the business, Cloudflare’s aim is to build a better and safer internet. Some of the company’s potential growth drivers include serverless computing, internet of things (IoT), and 5G. These present massive opportunities for the company to tap into. With more businesses moving their operations to the cloud, Cloudflare could see explosive growth in this burgeoning cybersecurity industry. That’s because of its role in safeguarding and speeding up the internet.From the company’s first-quarter earnings, revenue came in 51% higher year-over-year to $138.1 million. The network security and content delivery network (CDN) provider also sees strong large customer growth, with a record addition of roughly 120 large customers in the quarter. More importantly, large customers now represent greater than 50% of revenue. Following these earnings, NET stock has surged more than 20% over the past month. With such strong fundamentals, should investors buy NET stock right now?SquareSquare is another growth stock to watch capitalizing on the fintech megatrend. It combines software with hardware to enable sellers to utilize mobile devices and computing devices for payments and point-of-sale solutions. It has played a vital role in the digital economy and has empowered millions to shift to its digital payment solutions.If you have been keeping up with the lateststock market news, you have likely heard of meme stocks. And when it comes tomeme stocks, AMC Entertainment (NYSE: AMC) will most probably be the first to pop up in your mind. But in our article today, we are more interested in BlackBerry as it is at the forefront of two of the biggest trends today, namely IT security and autonomous driving. The meme stocks rally is sending BB stock at least 70% higher over the past week.From its first-quarter fiscal earnings, gross profit came in 79% higher year-over-year to $964 million. In detail, Square’s Seller ecosystem generated $468 million in gross profit for the quarter, a 32% increase compared to a year earlier. Also, its Cash App generated a whopping $495 million in gross profit, an increase of 171% year-over-year. Total net revenue for the quarter was $5.06 billion, up by 266% year-over-year. If anything, the company has also shown commendable resilience. Despite strict lockdowns around the world, its Seller’s gross profit continued to grow. All things considered, will you add SQ stock to your portfolio?ZyngaAfter Gamestop (NYSE: GME), Zynga is probably the most discussed gaming company among millennials. Zynga is a company behind many successful mobile games, such asWords with FriendsandZynga Poker,just to name a few. Recently, Zynga announced the acquisition of game developer Rollic, which has launched the popular gamesHigh Heels!AndBlob Runner 3D.In addition, the company has also bought the Echtra game company, which is likely to strengthen Zynga’s development capabilities for future cross-platform projects.From its first-quarter earnings, revenue came in 68% higher year-over-year to $680 million. Following strong top-line growth, Zynga went on to raise its full-year 2021 guidance for revenue to $2.7 billion, representing a growth of 37% year-over-year. Considering the strong growth in its revenue, would you say that ZNGA stock is a top growth stock to buy and hold for the long run?Teladoc HealthThe last growth stock to watch on this list is Teladoc Health. No doubt, Teladoc did indeed benefit immensely from the pandemic. This came as no surprise seeing that the company’s plethora of telehealth services remain a vital service during the pandemic. Considering it has shed around 50% of its value since peaking in February, many investors are seeing this as an opportunity to buy TDOC stock at great discounts. Teladoc Health reported its first-quarter financials on April 28. In it, it raised full-year guidance as first-quarter revenue came in 151% higher year-over-year to a record $453.7 million.One reason why investors are bullish is that Teladoc is slowly creating cheaper remote alternatives to the inconvenient, inefficient health care system we have today. Also, consulting firm McKinsey & Company projects that the U.S. virtual care market could approach $250 billion annually after the pandemic is over. The fact that more players are getting into telemedicine is a validation of the market potential here. Teladoc’s strategic maneuvers in the past years have cemented its position as a leader in its space. Therefore, it seems to me that TDOC stock has a potentially long growth runway ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":60,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119365497,"gmtCreate":1622520753719,"gmtModify":1634100856320,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Wow.. price was up so much.&nbsp;","listText":"Wow.. price was up so much.&nbsp;","text":"Wow.. price was up so much.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119365497","repostId":"1105273964","repostType":4,"repost":{"id":"1105273964","pubTimestamp":1622511256,"share":"https://www.laohu8.com/m/news/1105273964?lang=&edition=full","pubTime":"2021-06-01 09:34","market":"us","language":"en","title":"Here Are the 11 Best Performing IPOs of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1105273964","media":"Barron's","summary":"The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.That left us with 11 names. First up:CureVac, which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its ","content":"<p>The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.</p><p>But not everyone receives these types of opportunities. Most retail investors have to wait until companies start publicly trading to buy stock.<i>Barron’s</i>looked at businesses that have gone public in the past 12 months to find some strong performers.</p><p>First, we searched for companies that listed via a traditional initial public offering: This meant we filtered out businesses that merged withspecial purpose acquisition companies, or SPACs. Then, we searched for companies that went public on either the New York Stock Exchange or the Nasdaq. We also focused on entities that had at least a $1 billion market capitalization. We narrowed our search to companies with the highesttotal returns from their stock offering prices..</p><p>That left us with 11 names. First up:CureVac(ticker: CVAC), which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its first day, with the stock closing at $55.90. In January, CureVacstruck a deal with Bayerto accelerate the development and supply of its Covid-19 vaccine candidate. The company’s mRNA-based Covid-19 vaccine is now in clinical trials, and Phase2b/3 data is expected this summer. Since its IPO, the stock has nearly doubled, closingFriday at $111.48 .</p><p>Strong performances need not be dictated by success on the first day of trading. Four of the companies that made our list were busted deals—meaning that their shares fell below their IPO prices on the first day of trading.</p><p>Case in point:ZIM Integrated Shipping(ZIM). The asset-light shipping company went public in January with a $15 offering price,but closed that day at $11.50. Yet by May 19, ZIM’s stockhad gained 295%after itreported first-quarter earnings of $589.6 million, or $5.35 a share. The companyalso declared a special cash dividend of $2 a share. ZIM is the second-best-performing IPO in the past 12 months, based on a total return of 209.33%, according to FactSet. It closed on Friday at $46.40.</p><p>Another example isAcademy Sports &amp; Outdoors(ASO): The companywent public in Octoberwith a $13 offering price, with the stock closing at $12.99 during its first day of public trading<b>.</b>Academy was profitable when it went public, a rarity in the IPO market. InMarch, the company reported that its net incomesoared 416%, to $91.5 million, or 97 cents a share, for its fourth fiscal quarter ended Jan. 30. Its shares have nearly tripled since the IPO, and were trading at $36.53 on Friday. Academy Sports ranks third with a total return from the offering price of 181%, FactSet said.</p><p>Strong GainersThese companies all went public in the last year and produced high total returns compared to their IPO prices.<img src=\"https://static.tigerbbs.com/9dedc209ede147958c015d3a586bb587\" tg-width=\"630\" tg-height=\"606\">Rounding out this category areCorsair Gaming(CRSR), a California companythat makes performance gear for gamers, and the Dubai-basedYalla Group(YALA), whichmakes a voice-chat app usedin the Middle East and North Africa called Yalla. Both stocks have rebounded strongly after less-than-stellar September IPOs.</p><p>Some companies that made our list soared during their debuts, but have since seen their shares retreat. Still, these companies are producing gains.</p><p>ConsiderBigCommerce(BIGC), which provides a cloud e-commerce platform that is used by such customers as SkullCandy, Savannah Bee Co, and the Cleveland Cavaliers.BigCommerce&nbsp;went public in Augustwith a $24 offering price—and the stock soared 201% that day,closing at $72.27. Since the IPO, the shares have fallen nearly 25%, amid a broader technology selloff.</p><p>The company, however, has reported some positive developments, like a deal in February that wouldgive BigCommerce customersthe ability to sell directly on Walmart Marketplace. It also reported better-than-expected fourth-quarter results. BigCommerce has produced a total return of nearly 127%, according to FactSet.</p><p>Other companies have seen their shares jump since going public.Dream Finders Homes (DFH), which designs, builds, and sells homes in high-growth markets, was already profitable when it made its trading debut in January at $13 a share. Shares soared 61%, $20.95 on its first day.Prices for houses in Marchgrew at the fastest rate since 2005, which has helped real estate stocks. Dream Finders stock has gained nearly 52% since its IPO, trading Friday at $31.77. Dream Finders notched a total return from offering price of 144.38%.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here Are the 11 Best Performing IPOs of the Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere Are the 11 Best Performing IPOs of the Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/here-are-the-11-best-performing-ipos-of-the-year-51622472529?mod=hp_DAY_0><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.But not everyone receives these ...</p>\n\n<a href=\"https://www.barrons.com/articles/here-are-the-11-best-performing-ipos-of-the-year-51622472529?mod=hp_DAY_0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/here-are-the-11-best-performing-ipos-of-the-year-51622472529?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105273964","content_text":"The market for initial public offerings has recently delivered some great first-day gains for investors who were able to get shares before the companies went public.But not everyone receives these types of opportunities. Most retail investors have to wait until companies start publicly trading to buy stock.Barron’slooked at businesses that have gone public in the past 12 months to find some strong performers.First, we searched for companies that listed via a traditional initial public offering: This meant we filtered out businesses that merged withspecial purpose acquisition companies, or SPACs. Then, we searched for companies that went public on either the New York Stock Exchange or the Nasdaq. We also focused on entities that had at least a $1 billion market capitalization. We narrowed our search to companies with the highesttotal returns from their stock offering prices..That left us with 11 names. First up:CureVac(ticker: CVAC), which was the screen’s best-performing IPO and had a total return of 596.75%. CureVac specializes in the messenger RNA, or mRNA, technology that is the basis of several leading Covid-19 vaccine programs. The German biotech company went public inAugust at $16 a shareand soared 249% in its first day, with the stock closing at $55.90. In January, CureVacstruck a deal with Bayerto accelerate the development and supply of its Covid-19 vaccine candidate. The company’s mRNA-based Covid-19 vaccine is now in clinical trials, and Phase2b/3 data is expected this summer. Since its IPO, the stock has nearly doubled, closingFriday at $111.48 .Strong performances need not be dictated by success on the first day of trading. Four of the companies that made our list were busted deals—meaning that their shares fell below their IPO prices on the first day of trading.Case in point:ZIM Integrated Shipping(ZIM). The asset-light shipping company went public in January with a $15 offering price,but closed that day at $11.50. Yet by May 19, ZIM’s stockhad gained 295%after itreported first-quarter earnings of $589.6 million, or $5.35 a share. The companyalso declared a special cash dividend of $2 a share. ZIM is the second-best-performing IPO in the past 12 months, based on a total return of 209.33%, according to FactSet. It closed on Friday at $46.40.Another example isAcademy Sports & Outdoors(ASO): The companywent public in Octoberwith a $13 offering price, with the stock closing at $12.99 during its first day of public trading.Academy was profitable when it went public, a rarity in the IPO market. InMarch, the company reported that its net incomesoared 416%, to $91.5 million, or 97 cents a share, for its fourth fiscal quarter ended Jan. 30. Its shares have nearly tripled since the IPO, and were trading at $36.53 on Friday. Academy Sports ranks third with a total return from the offering price of 181%, FactSet said.Strong GainersThese companies all went public in the last year and produced high total returns compared to their IPO prices.Rounding out this category areCorsair Gaming(CRSR), a California companythat makes performance gear for gamers, and the Dubai-basedYalla Group(YALA), whichmakes a voice-chat app usedin the Middle East and North Africa called Yalla. Both stocks have rebounded strongly after less-than-stellar September IPOs.Some companies that made our list soared during their debuts, but have since seen their shares retreat. Still, these companies are producing gains.ConsiderBigCommerce(BIGC), which provides a cloud e-commerce platform that is used by such customers as SkullCandy, Savannah Bee Co, and the Cleveland Cavaliers.BigCommerce went public in Augustwith a $24 offering price—and the stock soared 201% that day,closing at $72.27. Since the IPO, the shares have fallen nearly 25%, amid a broader technology selloff.The company, however, has reported some positive developments, like a deal in February that wouldgive BigCommerce customersthe ability to sell directly on Walmart Marketplace. It also reported better-than-expected fourth-quarter results. BigCommerce has produced a total return of nearly 127%, according to FactSet.Other companies have seen their shares jump since going public.Dream Finders Homes (DFH), which designs, builds, and sells homes in high-growth markets, was already profitable when it made its trading debut in January at $13 a share. Shares soared 61%, $20.95 on its first day.Prices for houses in Marchgrew at the fastest rate since 2005, which has helped real estate stocks. Dream Finders stock has gained nearly 52% since its IPO, trading Friday at $31.77. Dream Finders notched a total return from offering price of 144.38%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":865841794,"gmtCreate":1632970083566,"gmtModify":1632970083724,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/865841794","repostId":"2171332039","repostType":4,"repost":{"id":"2171332039","pubTimestamp":1632967740,"share":"https://www.laohu8.com/m/news/2171332039?lang=&edition=full","pubTime":"2021-09-30 10:09","market":"us","language":"en","title":"Meme traders see red as heavily-shorted stocks grow scarcer and old names fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2171332039","media":"MarketWatch","summary":"Investors trading meme stocks spent Wednesday looking at a lot of red.\nThe unofficial meme-stock ind","content":"<p>Investors trading meme stocks spent Wednesday looking at a lot of red.</p>\n<p>The unofficial meme-stock index took a uniform pounding on Wednesday, with major names down significantly, and even a meme rotation into clean-energy names looked to slow down as retail investors found themselves playing an uneventful game of Whack-a-Mole trying to find heavily-shorted stocks to play for squeezes.</p>\n<p>But while the trading was ugly, retail investors took a macro thrill in signs that legal waters are getting choppy for their old frenemy Robinhood.</p>\n<p>Ur-memes like GameStop, AMC Entertainment, Blackberry&nbsp;and Koss&nbsp;all closed down to continue a rough weekly trend, and even new names like <a href=\"https://laohu8.com/S/CLNE\">Clean Energy Fuels Corp</a>&nbsp;and Canoo&nbsp;could not benefit from what seemed like early-week momentum of meme-stock traders plunging into renewable and green-energy names.</p>\n<p>But one name did manage to capitalize on that still-barely-breathing trend.</p>\n<p><a href=\"https://laohu8.com/S/CEI\">Camber Energy</a>&nbsp;closed up 6.2% after surging more than 30% in early trading. Camber, which saw a massive spike in social-media interest from retail traders on WallStreetBets, according to data from HypeEquity, also started the day as one of the most heavily shorted stocks on the market.</p>\n<p>Per a research note from Fintel, \"Raw short interest in Camber jumped from 6.1M shares as of August 31 to 24.4M shares on September 15, a colossal jump of 298%.\"</p>\n<p>For Camber, the old alchemy of heavy short interest and high social-media interest combined to give the natural-gas outfit big meme energy on Wednesday.</p>\n<p>That was not true for other heavily shorted names, however. Katapult Holdings Inc.&nbsp;fell 5%, e-commerce play Aterian&nbsp;plummeted 12.4%, and Vinco Ventures&nbsp;fell 3.2%.</p>\n<p>Even newly-listed hipster eyewear sweetheart Warby Parker failed to gain meme steam, giving up a midday surge to close up just 0.8%.</p>\n<p>But not all was dark and dreary on Reddit boards Wednesday, thanks to more potential legal schadenfreude coming from Robinhood HQ.</p>\n<p>In yet another class-action lawsuit filed on behalf of retail traders related to the zero-commission trading app's decision to halt trading on meme stocks on Jan. 28, at the height of the chaotic short squeeze, it was alleged that internal communications at Robinhood appear to indicate that the company's chief operating officer was unloading his shares in AMC just days before the app restricted trading on the stock.</p>\n<p>According to the filing, Jim Swartwout told colleagues via an internal chat on Jan. 26 \"I sold my AMC today.\"</p>\n<p>He followed up by warning fellow Robinhooders that \"FYI -- tomorrow morning we are moving GME to 100% -- so you are aware,\" apparently referring to the margin costs that Robinhood would be paying to hold the super-volatile stock on Jan. 27, one full day before the decision to restrict access was made.</p>\n<p>On Jan. 28, the company did restrict trading on both stocks, and others, after realizing it could no longer risk the margin costs.</p>\n<p>That move would have potentially protected Swartwout from taking losses on AMC shares that had surged almost 900% that month but would fall by 56% in the following days after Robinhood cut off access on its platform.</p>\n<p>The lawsuit was circulating widely by Wednesday afternoon, prompting a surge of subreddits dedicated to speculation on Swartwout's personal stock trading and a flurry of tweets casting suspicion on the purported stock dealings, and using them as yet more potential evidence to prove that anti-retail chicanery was a very real phenomenon at the height of January's squeeze.</p>\n<p>Neither Swartwout or Robinhood responded for comment on the lawsuit.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme traders see red as heavily-shorted stocks grow scarcer and old names fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme traders see red as heavily-shorted stocks grow scarcer and old names fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 10:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/meme-traders-see-red-as-heavily-shorted-stocks-grow-scarcer-and-old-names-fall-11632955167?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors trading meme stocks spent Wednesday looking at a lot of red.\nThe unofficial meme-stock index took a uniform pounding on Wednesday, with major names down significantly, and even a meme ...</p>\n\n<a href=\"https://www.marketwatch.com/story/meme-traders-see-red-as-heavily-shorted-stocks-grow-scarcer-and-old-names-fall-11632955167?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","WRBY":"Warby Parker Inc.","KOSS":"高斯电子","CLNE":"Clean Energy Fuels Corp","GOEV":"Canoo Inc.","ATER":"Aterian Inc.","BBIG":"Vinco Ventures, Inc.","AMC":"AMC院线","HOOD":"Robinhood","BB":"黑莓","KPLT":"Katapult Holdings, Inc.","CEI":"Camber Energy"},"source_url":"https://www.marketwatch.com/story/meme-traders-see-red-as-heavily-shorted-stocks-grow-scarcer-and-old-names-fall-11632955167?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2171332039","content_text":"Investors trading meme stocks spent Wednesday looking at a lot of red.\nThe unofficial meme-stock index took a uniform pounding on Wednesday, with major names down significantly, and even a meme rotation into clean-energy names looked to slow down as retail investors found themselves playing an uneventful game of Whack-a-Mole trying to find heavily-shorted stocks to play for squeezes.\nBut while the trading was ugly, retail investors took a macro thrill in signs that legal waters are getting choppy for their old frenemy Robinhood.\nUr-memes like GameStop, AMC Entertainment, Blackberry and Koss all closed down to continue a rough weekly trend, and even new names like Clean Energy Fuels Corp and Canoo could not benefit from what seemed like early-week momentum of meme-stock traders plunging into renewable and green-energy names.\nBut one name did manage to capitalize on that still-barely-breathing trend.\nCamber Energy closed up 6.2% after surging more than 30% in early trading. Camber, which saw a massive spike in social-media interest from retail traders on WallStreetBets, according to data from HypeEquity, also started the day as one of the most heavily shorted stocks on the market.\nPer a research note from Fintel, \"Raw short interest in Camber jumped from 6.1M shares as of August 31 to 24.4M shares on September 15, a colossal jump of 298%.\"\nFor Camber, the old alchemy of heavy short interest and high social-media interest combined to give the natural-gas outfit big meme energy on Wednesday.\nThat was not true for other heavily shorted names, however. Katapult Holdings Inc. fell 5%, e-commerce play Aterian plummeted 12.4%, and Vinco Ventures fell 3.2%.\nEven newly-listed hipster eyewear sweetheart Warby Parker failed to gain meme steam, giving up a midday surge to close up just 0.8%.\nBut not all was dark and dreary on Reddit boards Wednesday, thanks to more potential legal schadenfreude coming from Robinhood HQ.\nIn yet another class-action lawsuit filed on behalf of retail traders related to the zero-commission trading app's decision to halt trading on meme stocks on Jan. 28, at the height of the chaotic short squeeze, it was alleged that internal communications at Robinhood appear to indicate that the company's chief operating officer was unloading his shares in AMC just days before the app restricted trading on the stock.\nAccording to the filing, Jim Swartwout told colleagues via an internal chat on Jan. 26 \"I sold my AMC today.\"\nHe followed up by warning fellow Robinhooders that \"FYI -- tomorrow morning we are moving GME to 100% -- so you are aware,\" apparently referring to the margin costs that Robinhood would be paying to hold the super-volatile stock on Jan. 27, one full day before the decision to restrict access was made.\nOn Jan. 28, the company did restrict trading on both stocks, and others, after realizing it could no longer risk the margin costs.\nThat move would have potentially protected Swartwout from taking losses on AMC shares that had surged almost 900% that month but would fall by 56% in the following days after Robinhood cut off access on its platform.\nThe lawsuit was circulating widely by Wednesday afternoon, prompting a surge of subreddits dedicated to speculation on Swartwout's personal stock trading and a flurry of tweets casting suspicion on the purported stock dealings, and using them as yet more potential evidence to prove that anti-retail chicanery was a very real phenomenon at the height of January's squeeze.\nNeither Swartwout or Robinhood responded for comment on the lawsuit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":832073792,"gmtCreate":1629550922816,"gmtModify":1633684081515,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Wow. Rise somemore","listText":"Wow. Rise somemore","text":"Wow. Rise somemore","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/832073792","repostId":"2161149745","repostType":4,"repost":{"id":"2161149745","pubTimestamp":1629498960,"share":"https://www.laohu8.com/m/news/2161149745?lang=&edition=full","pubTime":"2021-08-21 06:36","market":"us","language":"en","title":"Bitcoin rises 5 percent to $49,106","url":"https://stock-news.laohu8.com/highlight/detail?id=2161149745","media":"StreetInsider","summary":"(Reuters) - Bitcoin rose 5.01 % to $49,106.4 at 22:04 GMT on Friday, adding $2,342.1 to its previous","content":"<p><img src=\"https://static.tigerbbs.com/e0b53399a7d28656bb2d3f7824cf0bea\" tg-width=\"200\" tg-height=\"135\" referrerpolicy=\"no-referrer\"></p>\n<p>(Reuters) - Bitcoin rose 5.01 % to $49,106.4 at 22:04 GMT on Friday, adding $2,342.1 to its previous close.</p>\n<p>Bitcoin, the world's biggest and best-known cryptocurrency, is up 77.4% from the year's low of $27,734 on Jan. 4.</p>\n<p>Ether, the coin linked to the ethereum blockchain network, rose 3.03% to $3,281.82 on Friday, adding $96.64 to its previous close.</p>\n<p>(Reporting by Radhika Anilkumar in Bengaluru; Editing by Sonya Hepinstall)</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin rises 5 percent to $49,106</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin rises 5 percent to $49,106\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-21 06:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18847810><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Bitcoin rose 5.01 % to $49,106.4 at 22:04 GMT on Friday, adding $2,342.1 to its previous close.\nBitcoin, the world's biggest and best-known cryptocurrency, is up 77.4% from the year's low ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18847810\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18847810","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161149745","content_text":"(Reuters) - Bitcoin rose 5.01 % to $49,106.4 at 22:04 GMT on Friday, adding $2,342.1 to its previous close.\nBitcoin, the world's biggest and best-known cryptocurrency, is up 77.4% from the year's low of $27,734 on Jan. 4.\nEther, the coin linked to the ethereum blockchain network, rose 3.03% to $3,281.82 on Friday, adding $96.64 to its previous close.\n(Reporting by Radhika Anilkumar in Bengaluru; Editing by Sonya Hepinstall)","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138830601,"gmtCreate":1621923994903,"gmtModify":1634185448274,"author":{"id":"3578292165234013","authorId":"3578292165234013","name":"CindyXinShou","avatar":"https://static.tigerbbs.com/8d250cc3d1bb2ee9509a8470d2ced7aa","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578292165234013","idStr":"3578292165234013"},"themes":[],"htmlText":"Glad to hear that and hope Tesla keep going!","listText":"Glad to hear that and hope Tesla keep going!","text":"Glad to hear that and hope Tesla keep going!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/138830601","repostId":"1136978816","repostType":4,"repost":{"id":"1136978816","pubTimestamp":1621922250,"share":"https://www.laohu8.com/m/news/1136978816?lang=&edition=full","pubTime":"2021-05-25 13:57","market":"us","language":"en","title":"Why Tesla Stock Jumped on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1136978816","media":"Motley Fool","summary":"What happened\nShares of electric car companyTesla(NASDAQ:TSLA)surged higher on Monday. Shares were u","content":"<p><b>What happened</b></p>\n<p>Shares of electric car company<b>Tesla</b>(NASDAQ:TSLA)surged higher on Monday. Shares were up about 5.7% as of 3:30 p.m. EDT.</p>\n<p>Thegrowth stock's gain was fueled both by a bullish day in the stock market and news that Tesla has reportedly entered into an agreement with<b>Luminar Technologies</b>(NASDAQ:LAZR)for testing and development of Luminar's laser-sensor technology.</p>\n<p><b>So what</b></p>\n<p>Highlighting why the overall market likely helped Tesla stock's gain on Monday, the<b>Nasdaq Composite</b>was up more than 1.6% as of this writing -- and many growth stocks like Tesla were up several percentage points or more.</p>\n<p>Meanwhile, news that Tesla is reportedly open to testing the laser-sensor technologies for autonomous driving that CEO Elon Musk has previously heavily criticized may have investors more confident in the company's long-term self-driving technology roadmap.</p>\n<p>Though Tesla stock is up today, it's still down about 14% year to date and 32% below its 52-week high.</p>\n<p><b>Now what</b></p>\n<p>Given the stock's enormous run-up last year and its recent sharp decline, there's likely plenty of volatility ahead for Tesla stock.</p>\n<p>Investors, however, should remain focused on the company's underlying business. Though Tesla's sales are growing rapidly, the company is still heavily dependent on sales of zero-emission vehicle credits for much of its profitability. But management believes Tesla is on a path to eventually achieve industry-leading operating margins.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla Stock Jumped on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla Stock Jumped on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 13:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/24/why-tesla-stock-jumped-on-monday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of electric car companyTesla(NASDAQ:TSLA)surged higher on Monday. Shares were up about 5.7% as of 3:30 p.m. EDT.\nThegrowth stock's gain was fueled both by a bullish day in the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/24/why-tesla-stock-jumped-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/05/24/why-tesla-stock-jumped-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136978816","content_text":"What happened\nShares of electric car companyTesla(NASDAQ:TSLA)surged higher on Monday. Shares were up about 5.7% as of 3:30 p.m. EDT.\nThegrowth stock's gain was fueled both by a bullish day in the stock market and news that Tesla has reportedly entered into an agreement withLuminar Technologies(NASDAQ:LAZR)for testing and development of Luminar's laser-sensor technology.\nSo what\nHighlighting why the overall market likely helped Tesla stock's gain on Monday, theNasdaq Compositewas up more than 1.6% as of this writing -- and many growth stocks like Tesla were up several percentage points or more.\nMeanwhile, news that Tesla is reportedly open to testing the laser-sensor technologies for autonomous driving that CEO Elon Musk has previously heavily criticized may have investors more confident in the company's long-term self-driving technology roadmap.\nThough Tesla stock is up today, it's still down about 14% year to date and 32% below its 52-week high.\nNow what\nGiven the stock's enormous run-up last year and its recent sharp decline, there's likely plenty of volatility ahead for Tesla stock.\nInvestors, however, should remain focused on the company's underlying business. Though Tesla's sales are growing rapidly, the company is still heavily dependent on sales of zero-emission vehicle credits for much of its profitability. But management believes Tesla is on a path to eventually achieve industry-leading operating margins.","news_type":1},"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}